Ärzt:innen

• klinische Transfusionsmedizin

Positionen und Funktionen

• seit 02/2019 Fachärztin an der Universitätsklinik für Transfusionsmedizin und Zelltherapie am AKH Wien

Ausbildung

• Seit 01/2019 Fachärztin für Blutgruppenserologie und Transfusionsmedizin (Ausbildung im Klinikum Hietzing [vormals KH Hietzing mit NZR:], AKH Wien und Hanusch KH)
• Seit 05/2017 Ärztin für Allgemeinmedizin (Ausbildung in div. KH des KAV)
• Seit 06/2017 DFP-Fortbildungsdiplom (ÖÄK-Diplom) und Notärztin (ÖÄK-Diplom)
• Seit 10/2020 GCP Diplom (GOOD CLINICAL PRACTICE)

Experimentelle und klinische Forschung

• Seit 02/2019 Wissenschaftliche Mitarbeit bei Klinischen Studien (Apeiron 401, Optimize und Atara)
• 06/2006–06/2007 Wissenschaftliche Mitarbeit an der Univ. Klinik für Innere Medizin II (Prof. DDr. Klappacher)
• 06/2005–05/2006 Wissenschaftliche Mitarbeit am Institut für Anatomie und Zellbiologie Medizinische Universität Wien (Prof. Dr. Bittner)
• 03/2003–05/2005 Wissenschaftliche Mitarbeit am Institut für Physiologie Medizinische Universität Wien (Prof. Dr. Reitsamer)

Mitgliedschaften

• Seit 2021 Mitglied der ÖGBT (Österreichische Gesellschaft für Blutgruppenserologie, Transfusionsmedizin, Regenerative Medizin und Immungenetik)

Beruflicher Werdegang

• seit 11/ 95 - Eintritt in die Universitätsklinik für Blutgruppenserologie und Transfusionsmedizin, Klinische Abteilung für Transfusionsmedizin, Medizinische Universität Wien/Allgemeines Krankenhaus der Stadt Wien
• 2003 - Ernennung zum a.o. Professor für das Fach „Immunhämatologie und Transfusionsmedizin“ an der Medizinischen Universität Wien
• 2002 - Habilitation für das Fach „Immunhämatologie und Transfusionsmedizin“ an der Medizinischen Fakultät der Universität Wien
• 2001 - Abschluss der Ausbildung zum Facharzt für Blutgruppenserologie und Transfusionsmedizin
• 01/95–10/95 - Wissenschaftlicher Angestellter am Institut für Tumorbiologie und Krebsforschung, Universität Wien
• 09/91–10/94 - im Rahmen des „Karl Landsteiner“-Stipendiums des Österreichischen Fonds zur Förderung der wissenschaftlichen Forschung Post-doctoral fellowship am Novartis Forschungsinstitut Wien
• 01/90–08/91 - Wissenschaftliche Tätigkeit in der Arbeitsgruppe um Herrn Prof. Dr. J. Teuber, Universität Heidelberg, Klinikum Mannheim
• 06/87–12/89 - Erstellung der medizinischen Promotionsarbeit am Deutschen Krebsforschungszentrum Heidelberg (Arbeitsgruppe um Herrn Prof. Dr. H. Kirchner; emerit. Direktor der Abteilung für Transfusionsmedizin, Universität Lübeck)

Berufliche Kenntnisse und Erfahrungen

1. Wissenschaftliches Umfeld

• Autor bzw. Co-Autor von mehr als 50 internationalen (peer-reviewed) Originalartikeln zu den Themenbereichen Transfusionsmedizin, zelluläre Therapie bzw. Immuntherapie. Autor bzw. Co-Autor von mehr als 70 wissenschaftlichen Kongressbeiträge und sonstigen wisenschaftlichen Veröffentlichungen aus dem Bereich Transfusionsmedizin/zelluläre Therapie.
• Review-Tätigkeiten für verschiedene internationale Zeitschriften, u.a. „Journal of Cellular and Molecular Medicine“ (IF: 6.9), „Thrombosis and Hemostasis“ (IF: 3.8), „Transfusion” (IF: 3.5), „Stem Cells and Development“ (IF: 3.3), „Therapeutic Apheresis and Dialysis” (IF: 1.3), und „Transfusion Medicine and Hematotherapy“ (IF: 0.5).
• Organisation und Vorsitzender bei verschiedenen nationalen und internationalen Symposia und Kongresse über Stammzellen und anderen zelluläre Therapieformen. Organisation und Vorsitz mehrerer post-gradueller Fortbildungsveranstaltungen zu transfusionsmedizinischen und zelltherapeutischen Themen, u.a. ISCT 2002, DGTI 2003, ISCT 2010.

2. Akademisches Umfeld

• Medizinische Leitung des Projekteams zum Neubau des GMP-konformen Laborbereiches „Zelltherapeutisches Labor“ an der Abteilung für Transfusionsmedizin, AKH Wien (166 m²-Sterilreinraum-Komplex der Sicherheitsklasse S3**; Projektgesamtkosten: € 3.5 Mio).
• Leiter des Bereiches „Lehre“ an der Abteilung für Transfusionsmedizin, Medizinische Universität Wien (2000–2015). Innerhalb dieser Tätigkeit Überführung der Lehrveranstaltung „Immunhämatologie“ in die Pflichtausbildung des Neuen Medizinischen Curriculum Wien. Wiederholte positive Evaluierung des Bereichs „Lehre“ gemäß ISO 9001:2000.
• Leiter des Laborbereiches „Durchflußzytometrie“ an der Abteilung für Transfusionsmedizin, Medizinische Universität Wien (1998–2001).
• Aufbau und Etablierung eines eigenständigen Forschungslabors an der Abteilung für Transfusionsmedizin, AKH Wien, erfolgreiche Einwerbung einer Forschungs-MTA.
• Mitglied im Planungsteam des Line-Elements „Diagnosewissenschaften“ gemäß dem Neuen Medizinischen Curriculum Wien. Kleingruppen-Koordinator innerhalb des Line-Elements gemäß dem Neuen Medizinischen Curriculum Wien.
• Erfolgreiche Anbahnung eines bilateralen Abkommens zwischen der Medizinischen Universität Wien und der Fujian Mecial University, Fuzhou, VR China (bilateraler Austausch von Studierenden, Lehrenden und Wissenschafter:innen zwischen beiden Universitäten).
• Externer Lehrauftrag an der University of Applied Sience Krems, Bereich Medizinische Biotechnologie; Thema: „Clinical use and therapeutic potential of cellular therapies“.
• Wiederholte Gastprofessuren an der Fujian Medical University; Fuzhou; Fujian Province, VR China bzw. an der Universität Vilnius, Vilnius, Litauen (gefördert durch das EURASIA-Pazific UniNet-Programm bzw. im Rahmen des EU geförderten ERASMUS-Programms). Konsulent für transfusionsmedizinische/ zelltherapeutische Fragestellungen an der Vilnius University, Vilnius, Litauen, und der Fujian Medical University, Fuzhou, VR China.
• Betreuung und Supervision von internationalen Gaststudierenden, post-docs und Gastärzt:innen an der Abteilung für Transfusionsmedizin, Medizinische Universität Wien.
• Betreuung und Supervision von in Summe 25 Diplom-, Magister- und Dissertationsarbeiten (Bakkalaureats-, Master-, PhD-Thesen).

3. Industrie

• Tätigkeit am Novartis Forschungsinstitut Wien; Mitarbeit bei der Entwicklung einer Antikörper-basierenden Anti-Tumortherapie. Zuteilung von zwei Patenten.
• Tätigkeit als Konsultant zu zelltherapeutischen Fragen bei verschiedenen Biotec-Unternehmen bzw. Start-up-Unternehmen, u.a. Sandoz AG, Dendreon, Sotio, Igeneon AG, Apeiron Biologicals.

Zusatzqualifikationen

• Teilnahme an dem dreisemestrigen Universitätslehrgang „Pharmazeutisches Qualitätsmanagement“, veranstaltet von der Universität Wien, 2011. Anerkennung als „Qualified Person“ gemäß EU-directive 2001/83/EC.
• Ausbildung als QM-Inspector gemäß der JACIE Kriterien (JACIE = Joint Accreditation Committee-ISCT & EBMT). Schwerpunktausbildung für die Bereiche Apherese und Labor, 2009.
• Teilnahme an dem Fortbildungskurs „Klinische Hämostasiologie“, veranstaltet von der Deutschen Gesellschaft für Hämostasiologie, Hannover, 2003.
• Teilnahme an dem Weiterbildungskursus „Molekularbiologie“,
  veranstaltet von der postgraduellen Kommission der Medizinischen Fakultät der Universität Wien, 1999.
• Ausbildung zum „Klinischen Prüfarzt“, veranstaltet von der Österreichischen Ärztekammer, 1999.
• Absolvierung des Ausbildungskursus zum „Notarzt“, veranstaltet
  von der Österreichischen Ärztekammer, 1999.
• Teilnahme am „3rd ESH-EBMT Postgraduate Training Course on Blood and Marrow Transplantation“, veranstaltet von der European School of Haematology, Potsdam, 1998.
• Teilnahme an verschiedener Strahlenschutzlehrgängen, veranstaltet
  von dem Österreichischen Forschungsinstitut Seibersdorf. Ausbildung
  zum Strahlenschutzbeauftragten für die Anwendung offener und
  geschlossener radioaktiver Stoffe, 1998.
• Amerikanisches Medizinisches Staatsexamen (FMGEMS);
  Clinical Science; (personal score: 79 %)

Stipendien/Förderungen/Auszeichnungen

• Zuteilung des „Karl-Landsteiner“-Stipendiums, ausgeschrieben vom Fonds zur Förderung der wissenschaftlichen Forschung, Wien. Im Rahmen des Stipendiums Bearbeitung des Forschungsprojektes mit dem Titel: „Interaction between monoclonal antibody therapy and the cellular immune system in patients treated with the blood group related antitumor antibody ABL 364“ (Projekt-Nummer L0033-MED).
• Jubiläumsfonds der Österreichische Nationalbank;
  „Untersuchungen zur Differenzierung humaner adulter Knochenmarkszellen“
  Förderungssumme: € 70.000,–.
• Medizinisch-Wissenschaftlicher Fonds des Bügermeisters der Stadt Wien;
  „Untersuchungen zur Myeloinsuffizienz bei Patienten mit chronisch lymphozytärer B-Zell Leukämie“
  Förderungssumme: € 21.800,–.
• Hochschuljubiläumsstiftung der Stadt Wien zur Förderung der Wissenschaft;
  „Untersuchungen zur Expression der SOCS (Suppressor of Cytokine Signaling) Gene in hämatopoietischen Vorläuferzellen“
  Förderungssumme: € 10.900,–.
• Zuteilung eines EU/ ERASMUS Stipendium (Lehrermobilität) durch die Medizinische Universität Wien über den Zeitraum 2006–2013.
• Im Rahmen der Tätigkeiten als Gastprofessor an der Fujian Medical University, Fuzhou, VR. China, Zuteilung wiederholter Stipendien durch das Eurasia-Pacific Uninet; 2009–2015.
• Wiederholte Abstract-Preise bei verschiedenen internationalen Kongresse, u.a. Abstract-Preis der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI); September 2008.
• Auszeichung als „Distinguished Guest Professor“, Fujian Medical University, Fuzhou, China.

• Immungenetik
• Transplantationsimmunolgie
• HLA
• KIR

Positions, Functions and Skills

• Since 1999 Quality Manager of the Department of Blood Group Serology and Transfusion Medicine
• Certified quality manager and auditor (ISO 9001)
• Since 03/1988 Head of the HLA/transplant immunology laboratory: HLA typing by serology, SSO, SSO, sequencing based typing
• Since 09/1987 Blood group typing, screening and crossmatches for red cell concentrates, identification of red cell specific antibodies

Education, Training

• 07/1999 Quality manager and auditor
• 08/1994 Board examination: Blood group serology and transfusion medicine
• 03/1993 Habilitation in blood group serology
• 1985 Graduation from Medical School: MD (Dr. univ. med.)
• 1978–1985 Medical School, University of Vienna

Research and scientific interests

• Since 1987 Scientific work at the Department of Blood Group Serology
• Initial focus molecular typing of the AB0 blood group system
• Currently: immunogenetics, particularly HLA and KIR systems
• 10/1991–09/1993 Sabbatical leave, visiting researcher at the Laboratory of Molecular Biology, Medical Research Council, Cambridge, UK; supervisor Dr. Cesar Milstein. Studies on somatic hypermutation of immunoglobulin genes (cloning and sequencing of immunoglobulin genes in mice)
• 03/1985–02/1987 Research grant of the Ministry of Sciences at the institute of Immunology, supervisor Prof. Walter Knapp: Cell biology of lymphocytes and granulocytes (tissue culture, flow cytometry, monocloncal antibodies)

Scientific societies, memberships

• Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI, member since 1985)
• Deutsche Gesellschaft für Immunologie (DGfI, member since 1986)
• Österreichische Gesellschaft für Hämatologie und Onkologie (ÖGHO, member since 1986)
• Deutsche Gesellschaft für Immungenetik, (DGI, member since 1992)
• Executive Board 1997–2001,
• President 2004–2006, 2008–2010
• European Federation of Immunogenetics (EFI, member since 1992)
• Councillor 1997–1999
• Member of the Committee for External Proficiency Testing 1999–2001
• Chairman of the Education Committee 2001–2003
• General Secretary of the Accreditation Committee 2006–2008
• Chairman of the Accreditation Committee 2008–2011
• President 2012–2015
• Councillor of the International Histocompatibility and Workshop Group since 2012

Publikationen

1) Osoegawa K., et al. A new strategy for systematically classifying HLA alleles into serological specificities. HLA 2022 https://doi.org/10.1111/tan.14662

2) Borski A. et al. Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection. Front Med (Lausanne) 2022; 9: 817127

3) Agerer B et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses Sci Immunol. 2021 6(57): eabg6461

4) Stary, V., et al. A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses. Sci Immunol 5(2020).

5) Osorio-Jaramillo, E., et al. Molecular-level HLA mismatch is associated with rejection and worsened graft survival in heart transplant recipients - a retrospective study. Transpl Int 33, 1078-1088 (2020).

6) Lang, C., et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med 8, 1057-1060 (2020).

7) Creary, L.E., et al. Next-generation HLA typing of 382 International Histocompatibility Working Group reference B-lymphoblastoid cell lines: Report from the 17th International HLA and Immunogenetics Workshop. Hum Immunol 80, 449-460 (2019).

8) Coti, I., et al. Donor-specific HLA antibodies after fresh decellularized vs cryopreserved native allograft implantation. HLA 96, 580-588 (2020).

9) Aigner C, Böhmig GA, Eskandary F, Herkner H, Prohászka Z, Csuka D, Kain R, Gaggl M, Sunder-Plassmann R, Müller-Sacherer T, Oszwald A, Fischer G, Schmidt A, Sunder-Plassmann G. Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients. Eur J Intern Med. 2020 Mar;73:51-58.

10) Koblischke M, Spitzer FS, Florian DM, Aberle SW, Malafa S, Fae I, Cassaniti I, Jungbauer C, Knapp B, Laferl H, Fischer G, Baldanti F, Stiasny K, Heinz FX, Aberle JH. CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection. Front Immunol. 2020 Jan 23;11:16.

11) Doberer K, Bond G, Kläger J, Regele H, Strassl R, Reindl-Schwaighofer R, Scheriau G, Wahrmann M, Kikić Ž, Faé I, Fischer G, Böhmig GA, Eskandary F. Immunoadsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. Blood Purif. 2020 Mar 19:1-10

12) Askar M, Madbouly A, Zhrebker L, Willis A, Kennedy S, Padros K, Rodriguez MB, Bach C, Spriewald B, Ameen R, Shemmari SA, Tarassi K, Tsirogianni A, Hamdy N, Mossallam G, Hönger G, Spinnler R, Fischer G, Fae I, Charlton R, Dunk A, Vayntrub TA, Halagan M, Osoegawa K, Fernández-Viña M. HLA Haplotypes In 250 Families: The Baylor Laboratory Results And A Perspective On A Core NGS Testing Model For The 17th International HLA And Immunogenetics Workshop. Hum Immunol. 2019 Nov;80(11):897-905.

13) Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R. Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood. 2019 Jul 11;134(2):199-210

14) Reindl-Schwaighofer R, Heinzel A, Kainz A, van Setten J, Jelencsics K, Hu K, Loza BL, Kammer M, Heinze G, Hruba P, Koňaříková A, Viklicky O, Boehmig GA, Eskandary F, Fischer G, Claas F, Tan JC, Albert TJ, Patel J, Keating B, Oberbauer R; iGeneTRAiN consortium. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. Lancet. 2019 Mar 2;393(10174):910-917.

15) Osoegawa K, Vayntrub TA, Wenda S, De Santis D, Barsakis K, Ivanova M, Hsu S, Barone J, Holdsworth R, Diviney M, Askar M, Willis A, Railton D, Laflin S, Gendzekhadze K, Oki A, Sacchi N, Mazzocco M, Andreani M, Ameen R, Stavropoulos-Giokas C, Dinou A, Torres M, Dos Santos Francisco R, Serra-Pages C, Goodridge D, Balladares S, Bettinotti MP, Iglehart B, Kashi Z, Martin R, Saw CL, Ragoussis J, Downing J, Navarrete C, Chong W, Saito K, Petrek M, Tokic S, Padros K, Beatriz Rodriguez M, Zakharova V, Shragina O, Marino SR, Brown NK, Shiina T, Suzuki S, Spierings E, Zhang Q, Yin Y, Morris GP, Hernandez A, Ruiz P, Khor SS, Tokunaga K, Geretz A, Thomas R, Yamamoto F, Mallempati KC, Gangavarapu S, Kanga U, Tyagi S, Marsh SGE, Bultitude WP, Liu X, Cao D, Penning M, Hurley CK, Cesbron A, Mueller C, Mytilineos J, Weimer ET, Bengtsson M, Fischer G, Hansen JA, Chang CJ, Mack SJ, Creary LE, Fernandez-Viña MA. Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop. Hum Immunol. 2019 Apr;80(4):228-236.

16) Faé I, Wenda S, Grill C, Fischer GF. HLA-B*44:138Q: Evidence for a confined deletion and recombination events in an otherwise unaffected HLA-haplotype. HLA. 2019 Feb;93(2-3):89-96

17) Müller C, Wendt J, Rauscher S, Sunder-Plassmann R, Richtig E, Fae I, Fischer G, Okamoto I. Risk Factors of Subsequent Primary Melanomas in Austria. JAMA Dermatol. 2019 Feb 1;155(2):188-195

18) Voorter CEM, Matern B, Tran TH, Fink A, Vidan-Jeras B, Montanic S, Fischer G, Fae I, de Santis D, Whidborne R, Andreani M, Testi M, Groeneweg M, Tilanus MGJ. Full-length extension of HLA allele sequences by HLA allele-specific hemizygous Sanger sequencing (SSBT) Hum Immunol. 2018 Nov;79(11):763-772

19) Wendt J, Mueller C, Rauscher S, Fae I, Fischer G, Okamoto I. Contributions by MC1R Variants to Melanoma Risk in Males and Females. JAMA Dermatol. 2018 Jul 1;154(7):789-795

20) Arnold ML, Bach C, Heinemann FM, Horn PA, Ziemann M, Lachmann N, Mühlbacher A, Dick A, Ender A, Thammanichanond D, Schaub S, Hönger G, Fischer GF, Mytilineos J, Hallensleben M, Hitzler WE, Seidl C, Spriewald BM. Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: Correlation with graft survival. Int J Immunogenet. 2018 Jun;45(3):

21) Koblischke M, Mackroth MS, Schwaiger J, Fae I, Fischer G, Stiasny K, Heinz FX, Aberle JH. Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination. Sci Rep. 2017 Aug 21;7(1):8907.

22) Wenda S, Faé I, Fischer GF.An HLA-B7-specific antibody in an HLA-B*07 positive patient explained by a nonexpressed allele (HLA-B*07:181N). HLA. 2017 Jul;90(1):32-35

23) Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC, Panicker S, Böhmig GA Effect of the Anti-C1s Humanized Antibody TNT009 and its Parental Mouse Variant TNT003 on HLA Antibody-induced Complement Activation - A Preclinical in Vitro Study. Am J Transplant. 2017 Mar 1

24) Böhmig GA, Fronek J, Slavcev A, Fischer GF, Berlakovich G, Viklicky O Czech-Austrian kidney paired donation: first European cross-border living donor kidney exchange. Transpl Int. 2017 Feb 25

25) Wendt J, Rauscher S, Burgstaller-Muehlbacher S, Fae I, Fischer G, Pehamberger H, Okamoto I.Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure. JAMA Dermatol. 2016 Apr 6.

26) Bojic M, Worel N, Sperr WR, Schellongowski P, Wohlfarth P, Schwarzinger I, Mitterbauer-Hohendanner G, Fischer G, Dieckmann KU, Lamm W, Leiner M, Schulenburg A, Mitterbauer M, Greinix HT, Kalhs P, Rabitsch W. Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation. Oncology. 2016;90(3):160-6

27) Müller C, Wendt J, Rauscher S, Burgstaller-Muehlbacher S, Sunder-Plassmann R, Scheurecker C, Richtig E, Fae I, Fischer G, Pehamberger H, Okamoto I Characterization of high risk melanoma patients in Austria. Br J Dermatol. 2016 Jan 22.

28) Schossleitner K, Habertheuer A, Finsterwalder R, Friedl HP, Rauscher S, Gröger M, Kocher A, Wagner C, Wagner SN, Fischer G, Schultz MJ, Wiedemann D, Petzelbauer P.

A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung Transplantation. PLoS One. 2015 Nov 4;10(11

29) Mack SJ, Milius RP, Gifford BD, Sauter J, Hofmann J, Osoegawa K, Robinson J, Groeneweg M, Turenchalk GS, Adai A, Holcomb C, Rozemuller EH, Penning MT, Heuer ML, Wang C, Salit ML, Schmidt AH, Parham PR, Müller C, Hague T, Fischer G, Fernandez-Viňa M, Hollenbach JA, Norman PJ, Maiers M.Minimum information for reporting next generation sequence genotyping (MIRING): Guidelines for reporting HLA and KIR genotyping via next generation sequencing. Hum Immunol. 2015 Dec;76(12):954-62

30) Freimüller C, Stemberger J, Artwohl M, Germeroth L, Witt V, Fischer G, Tischer S, Eiz-Vesper B, Knippertz I, Dörrie J, Schaft N, Lion T, Fritsch G, Geyeregger R.

Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions. Cytotherapy. 2015 Jul;17(7):989-1007

31) Kitzmüller C, Zulehner N, Roulias A, Briza P, Ferreira F, Faé I, Fischer GF, Bohle B.

Correlation of sensitizing capacity and T-cell recognition within the Bet v 1 family. J Allergy Clin Immunol. 2015 Jul;136(1):151-8.

32) Van Hemelen D, Mahler V, Fischer G, Fae I, Reichl-Leb V, Pickl W, Jutel M, Smolinska S, Ebner C, Bohle B, Jahn-Schmid B.HLA class II peptide tetramers vs allergen-induced proliferation for identification of allergen-specific CD4 T cells. Allergy. 2015 Jan;70(1):49-58

33) Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, Horowitz MM, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy JM, Velardi A, Witt CS, O'Huigin C, Apps R, Carrington M HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Blood. 2014 Dec 18;124

34) Deifl S, Kitzmüller C, Steinberger P, Himly M, Jahn-Schmid B, Fischer GF, Zlabinger GJ, Bohle B. Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of naïve CD4+ T cells from allergic patients. Allergy. 2014 Dec;69(12):1602-9

35) Leitner GC, Faschingbauer M, Wenda S, Weigel G, Fischer G.

Administration of recombinant human granulocyte-colony-stimulating factor does not induce long-lasting detectable epigenetic alterations in healthy donors. Transfusion. 2014 Dec;54(12):3121-6.

36) Schwaiger J, Aberle JH, Stiasny K, Knapp B, Schreiner W, Fae I, Fischer G, Scheinost O, Chmelik V, Heinz FX.Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction. J Virol. 2014 Jul;88(14):7828-42.

37) Geyeregger R, Freimüller C, Stemberger J, Fischer G, Witt V, Fritsch G.

Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation. Bone Marrow Transplant. 2014 Jul;49(7):934-41.

38) Nunes JM, Buhler S, Roessli D, Sanchez-Mazas A; HLA-net 2013 collaboration The HLA-net GENE[RATE] pipeline for effective HLA data analysis and its application to 145 population samples from Europe and neighbouring areas. Tissue Antigens. 2014 May;83(5):307-23.

39) Geyeregger R, Freimüller C, Stemberger J, Artwohl M, Witt V, Lion T, Fischer G, Lawitschka A, Ritter J, Hummel M, Holter W, Fritsch G, Matthes-Martin S.

First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother. 2014 May;37(4):245-9.

40) Wendt J, Rauscher S, Burgstaller-Mühlbacher S, Roka F, Fae I, Fischer G, Pehamberger H, Okamoto I.Actinic damage on the back is significantly determined by MC1R variants and previous sun exposure compared with other body sites in a multivariate analysis. Br J Dermatol. 2014 Sep;171(3):622-30.

41) Gabriel C, Furst D, Fae I, Wenda S, Zollikofer C, Mytilineos J und Fischer GF HLA typing by next-generation sequencing - getting closer to reality. 2014. Tissue antigens. 83:2, 65-75.

42) Wenda S, Fae I, Sanchez-Mazas A, Nunes JM, Mayr WR und Fischer GF The distribution of MICA alleles in an Austrian population: evidence for increasing polymorphism. 2013. Human immunology. 74:10, 1295-9.

43) Susal C, Roelen DL, Fischer G, Campos EF, Gerbase-DeLima M, Honger G, Schaub S, Lachmann N, Martorell J und Claas F Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. 2013. Tissue antigens. 82:2, 83-92.

44) Geyeregger R, Freimuller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, Lion T, Rammensee HG, Fischer G, Eiz-Vesper B, Lawitschka A, Matthes S und Fritsch G Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. 2013. PloS one. 8:4, e59592.

45) Mack SJ, Cano P, Hollenbach JA, He J, Hurley CK, Middleton D, Moraes ME, Pereira SE, Kempenich JH, Reed EF, Setterholm M, Smith AG, Tilanus MG, Torres M, Varney MD, Voorter CE, Fischer GF, Fleischhauer K, Goodridge D, Klitz W, Little AM, Maiers M, Marsh SG, Muller CR, Noreen H, Rozemuller EH, Sanchez-Mazas A, Senitzer D, Trachtenberg E und Fernandez-Vina M Common and well-documented HLA alleles: 2012 update to the CWD catalogue. 2013. Tissue antigens. 81:4, 194-203.

46) Arnold ML, Heinemann FM, Horn P, Ziemann M, Lachmann N, Muhlbacher A, Dick A, Ender A, Thammanichanond D, Fischer GF, Schaub S, Hallensleben M, Mytilineos J, Hitzler WE, Seidl C, Doxiadis, II und Spriewald BM 16(th) IHIW: anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates. 2013. International journal of immunogenetics. 40:1, 17-20.

47) Hollenbach JA, Augusto DG, Alaez C, Bubnova L, Fae I, Fischer G, Gonzalez-Galarza FF, Gorodezky C, Karabon L, Kusnierczyk P, Noble J, Rickards O, Roberts C, Schaffer M, Shi L, Tavoularis S, Trachtenberg E, Yao Y und Middleton D 16(th) IHIW: population global distribution of killer immunoglobulin-like receptor (KIR) and ligands. 2013. International journal of immunogenetics. 40:1, 39-45.

48) Wohrl S, Moritz KB, Bracher A, Fischer G, Stingl G und Loewe R A c-kit mutation in exon 18 in familial mastocytosis. 2013. The Journal of investigative dermatology. 133:3, 839-41.

49) Wahrmann M, Hlavin G, Fischer G, Marinova L, Schwaiger E, Horl WH, Zlabinger GJ, Kormoczi GF, Konig F und Bohmig GA Modified solid-phase alloantibody detection for improved crossmatch prediction. 2013. Human immunology. 74:1, 32-40.

50) Bohmig GA, Fidler S, Christiansen FT, Fischer Gund Ferrari P Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. 2013. Human immunology. 74:5, 500-5.

51) Garner-Spitzer E, Wagner A, Paulke-Korinek M, Kollaritsch H, Heinz FX, Redlberger-Fritz M, Stiasny K, Fischer GF, Kundi M und Wiedermann U Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10. 2013. Journal of immunology. 191:5, 2426-36.

52) Sanchez-Mazas A, Vidan-Jeras B, Nunes JM, Fischer G, Little AM, Bekmane U, Buhler S, Buus S, Claas FH, Dormoy A, Dubois V, Eglite E, Eliaou JF, Gonzalez-Galarza F, Grubic Z, Ivanova M, Lie B, Ligeiro D, Lokki ML, da Silva BM, Martorell J, Mendonca D, Middleton D, Voniatis DP, Papasteriades C, Poli F, Riccio ME, Vlachou MS, Sulcebe G, Tonks S, Nevessignsky MT, Vangenot C, van Walraven AM und Tiercy JM Strategies to work with HLA data in human populations for histocompatibility, clinical transplantation, epidemiology and population genetics: HLA-NET methodological recommendations. 2012. International journal of immunogenetics. 39:6, 459-72; quiz 73-6.

53) Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, Bozic L, Pelzmann B, Tuchler H, Fae I, Fischer GF, Greinix HT, Peters C, Kalhs P, Krieger O, Linkesch W, Nachbaur D, Urban C, Posch U, Lanzer G, Gabriel C, Schennach H und Mayr WR What are a patient's current chances of finding a matched unrelated donor? Twenty years' central search experience in a small country. 2012. Bone marrow transplantation. 47:2, 172-80.

54) Knapp B, Fischer G, Van Hemelen D, Fae I, Maillere B, Ebner C, Schreiner W, Bohle B und Jahn-Schmid B Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background. 2012. BMC immunology. 13, 43.

55) Karle AC, Oostingh GJ, Mutschlechner S, Ferreira F, Lackner P, Bohle B, Fischer GF, Vogt AB und Duschl A Nitration of the pollen allergen bet v 1.0101 enhances the presentation of bet v 1-derived peptides by HLA-DR on human dendritic cells. 2012. PloS one. 7:2, e31483.

56) Chen KW, Focke-Tejkl M, Blatt K, Kneidinger M, Gieras A, Dall'Antonia F, Fae I, Fischer G, Keller W, Valent P, Valenta R und Vrtala S Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. 2012. Allergy. 67:5, 609-21.

57) Rosenmayr A, Pointner-Prager M, Winkler M, Mitterschiffthaler A, Pelzmann B, Bozic L, Pichler SK, Tuchler H, Fae I und Fischer GThe Austrian Bone Marrow Donor Registry: Providing Patients in Austria with Unrelated Donors for Transplant - a Worldwide Cooperation. 2011. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 38:5, 292-99.

58) Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H und Sacchi N Definitions of histocompatibility typing terms. 2011. Blood. 118:23, e180-3.

59) Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H und Sacchi N Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. 2011. Human immunology. 72:12, 1214-6.

60) Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, Bozic L, Pelzmann B, Tuchler H, Fae I, Fischer GF, Greinix HT, Peters C, Kalhs P, Krieger O, Linkesch W, Nachbaur D, Urban C, Posch U, Lanzer G, Gabriel C, Schennach H und Mayr WR What are a patient's current chances of finding a matched unrelated donor? Twenty years' central search experience in a small country. 2012. Bone marrow transplantation. 47:2, 172-80.

61) Schulten V, Nagl B, Scala E, Bernardi ML, Mari A, Ciardiello MA, Lauer I, Scheurer S, Briza P, Jurets A, Ferreira F, Jahn-Schmid B, Fischer GF und Bohle B Pru p 3, the nonspecific lipid transfer protein from peach, dominates the immune response to its homolog in hazelnut. 2011. Allergy. 66:8, 1005-13.

62) Boehm A, Walcherberger B, Sperr WR, Wohrer S, Dieckmann K, Rosenmayr A, Pernicka E, Fischer G, Worel N, Mitterbauer G, Schwarzinger I, Mitterbauer M, Haas OA, Lechner K, Hinterberger W, Valent P, Greinix HT, Rabitsch W und Kalhs P.Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.2011. Biol Blood Marrow Transplant. 17:133-40

63) Trembleau S, Hoffmann M, Meyer B, Nell V, Radner H, Zauner W, Hammer J, Aichinger G, Fischer G, Smolen J und Steiner G.Immunodominant T-cell epitopes of hnRNP-A2 associated with disease activity in patients with rheumatoid arthritis.2010. Eur J Immunol. 40:1795-808

64) Nunes JM, Riccio ME, Buhler S, Di D, Currat M, Ries F, Almada AJ, Benhamamouch S, Benitez O, Canossi A, Fadhlaoui-Zid K, Fischer G, Kervaire B, Loiseau P, de Oliveira DC, Papasteriades C, Piancatelli D, Rahal M, Richard L, Romero M, Rousseau J, Spiroski M, Sulcebe G, Middleton D, Tiercy JM und Sanchez-Mazas A.Analysis of the HLA population data (AHPD) submitted to the 15th International Histocompatibility/Immunogenetics Workshop by using the Gene[rate] computer tools accommodating ambiguous data (AHPD project report).2010. Tissue Antigens. 76:18-30

65) Mutschlechner S, Egger M, Briza P, Wallner M, Lackner P, Karle A, Vogt AB, Fischer GF, Bohle B und Ferreira F.Naturally processed T cell-activating peptides of the major birch pollen allergen.2010. J Allergy Clin Immunol. 125:711-8, 718 e1-718 e2

66) Garritsen HS, Fae I, Legath N, Hannig H und Fischer GF.Identification of a novel HLA-DRB3*01 variant, HLA-DRB3*0114, containing a DRB1 sequence motif by micro-temperature gradient gel electrophoresis confirmed by sequence-based typing.2010. Tissue Antigens. 75:185-6

67) Bartel G, Wahrmann M, Regele H, Kikic Z, Fischer G, Druml W, Muhlbacher F und Bohmig GA.Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation.2010. Am J Transplant. 10:2033-42

68) Wahrmann M, Bartel G, Exner M, Regele H, Kormoczi GF, Fischer GF, Bohmig GA. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22 (10): 982.

69) Stiegler G, Fischer G, Ramanathan G, Bencur P, Weigel G, Mannhalter C. P-selectin mRNA is maintained in platelet concentrates stored at 4 degrees C. Transfusion 2009; 49 (5): 921.

70) Pfistershammer K, Lawitschka A, Klauser C, Leitner J, Weigl R, Heemskerk MH, Pickl WF, Majdic O, Bohmig GA, Fischer GF, Greinix HT, Steinberger P. Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood 2009; 114 (11): 2323.

71) Ludajic K, Rosenmayr A, Fae I, Fischer GF, Balavarca Y, Bickeboller H, Kalhs P, Greinix HT. Association of HLA-E polymorphism with the outcome of hematopoietic stem-cell transplantation with unrelated donors. Transplantation 2009; 88 (10): 1227.

72) Ludajic K, Balavarca Y, Bickeboller H, Rosenmayr A, Fischer GF, Fae I, Kalhs P, Pohlreich D, Kouba M, Dobrovolna M, Greinix HT. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 2009; 15 (11): 1400.

73) Ludajic K, Balavarca Y, Bickeboller H, Rosenmayr A, Fae I, Fischer GF, Kouba M, Pohlreich D, Kalhs P, Greinix HT. KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44 (2): 97.

74) Leb VM, Jahn-Schmid B, Kueng HJ, Schmetterer KG, Haiderer D, Neunkirchner A, Fischer GF, Hartl A, Thalhamer J, Steinberger P, Bohle B, Seed B, Pickl WF. Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. J Allergy Clin Immunol 2009; 124 (1): 121.

75) Kleinle S, Lang R, Fischer GF, Vierhapper H, Waldhauser F, Fodinger M, Baumgartner-Parzer SM. Duplications of the functional CYP21A2 gene are primarily restricted to Q318X alleles: evidence for a founder effect. J Clin Endocrinol Metab 2009; 94 (10): 3954.

76) Garritsen HS, Fae I, Legath N, Hannig H, Fischer GF. Identification of a novel HLA-DRB3*01 variant, HLA-DRB3*0114, containing a DRB1 sequence motif by micro-temperature gradient gel electrophoresis confirmed by sequence-based typing. Tissue Antigens 2009.

77) Doxiadis GG, de Groot N, Dauber EM, van Eede PH, Fae I, Faner R, Fischer G, Grubic Z, Lardy NM, Mayr W, Palou E, Swelsen W, Stingl K, Doxiadis, II, Bontrop RE. High resolution definition of HLA-DRB haplotypes by a simplified microsatellite typing technique. Tissue Antigens 2009; 74 (6): 486.

78) Ludajic K, Balavarca Y, Bickeboller H, Pohlreich D, Kouba M, Dobrovolna M, Vrana M, Rosenmayr A, Fischer GF, Fae I, Kalhs P, Greinix HT. Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT. Br J Haematol 2008; 142 (3): 436.

79) Leb VM, Jahn-Schmid B, Schmetterer KG, Kueng HJ, Haiderer D, Neunkirchner A, Fischer GF, Nissler K, Hartl A, Thalhamer J, Bohle B, Seed B, Pickl WF. Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol 2008; 121 (1): 64.

80) Jahn-Schmid B, Sirven P, Leb V, Pickl WF, Fischer GF, Gadermaier G, Egger M, Ebner C, Ferreira F, Maillere B, Bohle B. Characterization of HLA class II/peptide-TCR interactions of the immunodominant T cell epitope in Art v 1, the major mugwort pollen allergen. J Immunol 2008; 181 (5): 3636.

81) Holler E, Rogler G, Brenmoehl J, Hahn J, Greinix H, Dickinson AM, Socie G, Wolff D, Finke J, Fischer G, Jackson G, Rocha V, Hilgendorf I, Eissner G, Marienhagen J, Andreesen R. The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet 2008; 35 (4-5): 381.

82) Fae I, Rosenmayr A, Mayr WR, Fischer GF. A novel HLA-C allele, Cw*0617. Tissue Antigens 2008; 72 (5): 499.

83) Worel N, Greinix HT, Supper V, Leitner G, Mitterbauer M, Rabitsch W, Fischer G, Rosenmayr A, Hocker P, Kalhs P. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007; 47 (8): 1494.

84) Vidan-Jeras B, Ambroz N, Fae I, Kemperle I, Fischer G. HLA-B*350802, a novel allele, which has arisen by silent mutation at codon 67. Tissue Antigens 2007; 69 (4): 363.

85) Penn DJ, Oberzaucher E, Grammer K, Fischer G, Soini HA, Wiesler D, Novotny MV, Dixon SJ, Xu Y, Brereton RG. Individual and gender fingerprints in human body odour. J R Soc Interface 2007; 4 (13): 331.

86) Meraner P, Horejsi V, Wolpl A, Fischer GF, Stingl G, Maurer D. Dendritic cells sensitize TCRs through self-MHC-mediated Src family kinase activation. J Immunol 2007; 178 (4): 2262.

87) Leb VM, Jahn-Schmid B, Schmetterer KG, Kueng HJ, Haiderer D, Neunkirchner A, Fischer GF, Nissler K, Hartl A, Thalhamer J, Bohle B, Seed B, Pickl WF. Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol 2007.

88) Karvunidis T, Jindra P, Fischer G, Venigova P, Dorner A, Koza V. Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*1458, by sequence-based typing. Tissue Antigens 2007; 70 (4): 348.

89) Hoftberger R, Garzuly F, Dienes HP, Grubits J, Rohonyi B, Fischer G, Hanzely Z, Lassmann H, Budka H. Fulminant central nervous system demyelination associated with interferon-{alpha} therapy and hepatitis C virus infection. Mult Scler 2007; 13 (9): 1100.

90) Danzer M, Polin H, Proll J, Hofer K, Fae I, Fischer GF, Gabriel C. High-throughput sequence-based typing strategy for HLA-DRB1 based on real-time polymerase chain reaction. Hum Immunol 2007; 68 (11): 915.

91) Baumgartner-Parzer SM, Fischer G, Vierhapper H. Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene. J Clin Endocrinol Metab 2007; 92 (3): 1164.

92) Vidan-Jeras B, Kunilo S, Fae I, Kandus A, Fischer GF. A novel HLA-B*2730 allele found in a Slovene patient affected with IgA nephropathy. Int J Immunogenet 2006; 33 (5): 371.

93) Mrazek F, Fae I, Ambruzova Z, Raida L, Kriegova E, Indrak K, Fischer GF, Petrek M. A single amino acid exchange shifts the serological reactivity of the novel HLA-B*4442 allele product from HLA-B44 to HLA-B21. Int J Immunogenet 2006; 33 (3): 197.

94) Ludajic K, Fae I, Fischer GF. Characterization of a new HLA-DPB1 allele, DPB1*010103. Tissue Antigens 2006; 67 (3): 255.

95) Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H, Dickinson AM, Socie G, Wolff D, Fischer G, Jackson G, Rocha V, Steiner B, Eissner G, Marienhagen J, Schoelmerich J, Andreesen R. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107 (10): 4189.

96) Danzer M, Polin H, Fae I, Fischer GF, Gabriel C. Exon 1-4 sequence analysis of a novel HLA-A allele, HLA-A*2458. Tissue Antigens 2006; 68 (2): 177.

97) Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Potschger U, Rosenmayr A, Fischer G, Gadner H, Peters C. Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2005; 27 (10): 532.

98) Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Potschger U, Rosenmayr A, Fischer G, Gadner H, Peters C. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Haematologica 2005; 90 (10): 1405.

99) Mrazek F, Fae I, Ambruzova Z, Raida L, Indrak K, Petrek M, Fischer GF. A novel HLA-B*420502 allele identified by PCR-SSO/SSP routine typing and confirmed by Sequencing-based typing. Tissue Antigens 2005; 65 (3): 275.

100) Jahn-Schmid B, Fischer GF, Bohle B, Fae I, Gadermaier G, Dedic A, Ferreira F, Ebner C. Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. J Allergy Clin Immunol 2005; 115 (2): 399.

101) Greinix HT, Fae I, Schneider B, Rosenmayr A, Mitterschiffthaler A, Pelzmann B, Kalhs P, Lechner K, Mayr WR, Fischer GF. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant 2005; 35 (1): 57.

102) Bohle B, Zwolfer B, Fischer GF, Seppala U, Kinaciyan T, Bolwig C, Spangfort MD, Ebner C. Characterization of the human T cell response to antigen 5 from Vespula vulgaris (Ves v 5). Clin Exp Allergy 2005; 35 (3): 367.

103) Voorter CE, Fischer GF, van den Berg-Loonen EM. Identification of a new HLA-C allele, Cw*0316, by sequence-based typing. Tissue Antigens 2004; 63 (5): 484.

104) Loewe R, Kittler H, Fischer G, Fae I, Wolff K, Petzelbauer P. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 2004; 123 (4): 733.

105) Fae I, Lau M, Voorter C, Mayr WR, Fischer GF. HLA-B*8102*, a new allele found in an external proficiency testing scheme. Tissue Antigens 2004; 64 (5): 608.

106) Danzer M, Leitner D, Gangl E, Fae I, Fischer GF, Gabriel C. A novel HLA-DRB1*13 allele (DRB1*1357) identified by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 2004; 64 (2): 213.

107) Zettinig G, Tanew A, Fischer G, Mayr W, Dudczak R, Weissel M. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 131 (2): 347.

108) Winter D, Fiebiger E, Meraner P, Auer H, Brna C, Strohal R, Trautinger F, Knobler R, Fischer GF, Stingl G, Maurer D. Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 2003; 171 (5): 2714.

109) Vogelsang H, Panzer S, Mayr WR, Granditsch G, Fischer GF. Distribution of HLA class I alleles differs in celiac disease patients according to age of onset. Dig Dis Sci 2003; 48 (3): 611.

110) Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, Schernthaner G, Eibl MM. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003; 221 (1): 15.

111) Bohle B, Radakovics A, Jahn-Schmid B, Hoffmann-Sommergruber K, Fischer GF, Ebner C. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level. Eur J Immunol 2003; 33 (12): 3303.

112) Worel N, Greinix HT, Keil F, Mitterbauer M, Lechner K, Fischer G, Mayr W, Hocker P, Kalhs P. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002; 42 (10): 1293.

113) Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, Hocker P, Dieckmann K, Fischer G, Rosenmayr A, Linkesch W, Hinterberger W, Lechner K, Greinix HT. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant 2002; 30 (9): 619.

114) Tiercy JM, Marsh SG, Schreuder GM, Albert E, Fischer G, Wassmuth R. Guidelines for nomenclature usage in HLA reports: ambiguities and conversion to serotypes. Eur J Immunogenet 2002; 29 (3): 273.

115) Nachbaur D, Eibl B, Kropshofer G, Meister B, Mitterschiffthaler A, Schennach H, Fischer G, Kopp M, Gunsilius E, Gastl G. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002; 11 (4): 731.

116) Jahn-Schmid B, Kelemen P, Himly M, Bohle B, Fischer G, Ferreira F, Ebner C. The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J Immunol 2002; 169 (10): 6005.

117) Eibl N, Spatz M, Fischer GF, Mayr WR, Samstag A, Wolf HM, Schernthaner G, Eibl MM. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103 (3 Pt 1): 249.

118) Stockl J, Majdic O, Fischer G, Maurer D, Knapp W. Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-specific CTL. J Immunol 2001; 167 (5): 2724.

119) Fischer GF, Mayr WR. Molecular genetics of the HLA complex. Wien Klin Wochenschr 2001; 113 (20-21): 814.

120) Fischer GF, Fae I, Mann D, Kriks D, Jager W, Platzer W, Mayr WR, Volc-Platzer B. An HLA class-II allele frequent in Eskimos and Amerindians is found in the Tyrolean Ice Man. Ann Hum Genet 2001; 65 (Pt 4): 363.

121) Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knobl P, Reiter E, Derfler K, Fischer G, Hinterberger W, Hocker P, Kalhs P. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000; 40 (5): 543.

122) Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knobl P, Reiter E, Derfler K, Fischer G, Hinterberger W, Hocker P, Kalhs P. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems [In Process Citation]. Transfusion 2000; 40 (5): 543.

123) Panzer S, Janisiw M, Fischer G, Jilma B. The platelet alpha2-integrin (GPIa) nucleotide-807 polymorphism is not associated with a risk for maternal-fetal human platelet antigen-5 incompatibility. Ann Hematol 2000; 79 (6): 296.

124) Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F, Honigsmann H, Knobler RM. Extracorporeal photochemotherapy in the treatment of severe steroid- refractory acute graft-versus-host disease: a pilot study [In Process Citation]. Blood 2000; 96 (7): 2426.

125) Greinix HT, Loidolt H, Rabitsch W, Schulenburg A, Keil F, Mitterbauer M, Laczika K, Lechner K, Dieckmann K, Fischer G, Jager U, Rosenmayr A, Knobl P, Schwarzinger I, Hocker P, Mannhalter C, Hinterberger W, Haas OA, Fonatsch C, Kalhs P. Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia. Ann Hematol 2000; 79 (4): 206.

126) Fae I, Gleissner B, Kriks D, Leitner D, Fischer GF. Serological and nucleotide sequence analysis of HLA-A*6812. Tissue Antigens 2000; 56 (3): 276.

127) Fae I, Gleissner B, Kriks D, Leitner D, Fischer GF. Serological and nucleotide sequence analysis of HLA-A*6812 [In Process Citation]. Tissue Antigens 2000; 56 (3): 276.

128) Bohle B, Wagner B, Vollmann U, Buck D, Niggemann B, Szepfalusi Z, Fischer G, Scheiner O, Breiteneder H, Ebner C. Characterization of T cell responses to Hev b 3, an allergen associated with latex allergy in spina bifida patients. J Immunol 2000; 164 (8): 4393.

129) Anvari A, Janisiw M, Turel Z, Huber K, Fischer G, Panzer S. Platelet glycoprotein Ia gene dimorphism alpha2-807 in malignant arrhythmia in coronary artery disease. Thromb Res 2000; 98 (4): 281.

130) Reiter E, Greinix HT, Keil F, Brugger S, Rabitsch W, Schulenburg A, Mannhalter C, Schwarzinger I, Worel N, Volc-Platzer B, Fischer G, Dieckmann K, Hinterberger W, Schneider B, Haas OA, Geissler K, Kalhs P. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999; 78 (11): 507.

131) Peters C, Matthes-Martin S, Fritsch G, Holter W, Lion T, Witt V, Hocker P, Fischer G, Dieckmann K, Handgretinger R, Klingebiel T, Gadner H. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999; 13 (12): 2070.

132) Kalhs P, Brugger S, Reiter E, Keil F, Fischer G, Schulenburg A, Rabitsch W, Rosenmayr A, Dieckmann K, Kurz M, Schwarzinger I, Volc-Platzer B, Mannhalter C, Lechner K, Greinix HT. Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. Bone Marrow Transplant 1999; 23 (8): 753.

133) Groger M, Fischer GF, Wolff K, Petzelbauer P. Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaRIIa. J Invest Dermatol 1999; 113 (1): 56.

134) Fodinger M, Wolfl G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Horl WH, Sunder-Plassmann G. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999; 55 (3): 1072.

135) Drabek J, Bunce M, Fae I, Ambruzova Z, Dunn P, Ross J, Fischer GF. Characterization of a novel HLA-A*24 allele containing an HLA-A*03 sequence motif. Tissue Antigens 1999; 54 (1): 98.

136) Strohal R, Brna C, Mossbacher U, Fischer G, Pehamberger H, Stingl G. First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites. J Invest Dermatol 1998; 111 (6): 1085.

137) Strohal R, Brna C, Mossbacher U, Fischer G, Pehamberger H, Stingl G. First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites [published erratum appears in J Invest Dermatol 1999 Feb;112(2):256]. J Invest Dermatol 1998; 111 (6): 1085.

138) Reiter E, Greinix HT, Mitterbauer G, Fischer G, Keil F, Mannhalter C, Rabitsch W, Schwarzinger I, Worel N, Lechner K, Kalhs P. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. Ann Hematol 1998; 77 (6): 283.

139) Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, Schwarzinger I, Hocker P, Fischer G, Dieckmann K, Hinterberger W, Linkesch W, Schneider B, Lechner K, Kalhs P. Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transplant 1998; 22 Suppl 4: S86.

140) Rabitsch W, Reiter E, Keil F, Malzer R, Leitner G, Fischer G, Dieckman K, Kalhs P, Lechner K, Greinix HT. Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies. Bone Marrow Transplant 1998; 22 Suppl 4: S49.

141) Raber W, Fischer G, Vierhapper H. Consanguinity in question in two patients with congenital adrenal hyperplasia who bear an identical first and last name--second look. Wien Klin Wochenschr 1998; 110 (1): 23.

142) Greinix HT, Reiter E, Schulenburg A, Keil F, Lechner K, Fischer G, Rosenmayr A, Leitner G, Kalhs P. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. Bone Marrow Transplant 1998; 22 Suppl 4: S53.

143) Greinix HT, Reiter E, Keil F, Fischer G, Lechner K, Dieckmann K, Leitner G, Schulenburg A, Hoecker P, Haas OA, Knoebl P, Mannhalter C, Fonatsch C, Hinterberger W, Kalhs P. Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors. Bone Marrow Transplant 1998; 21 (7): 673.

144) Friedl-Hajek R, Breiteneder H, Bohle B, Fischer G, Ebner C, Scheiner O. Conserved sequence motifs of CDR3 loops of TCR specific for two major epitopes of the grass pollen allergen PhI p 1. Int Immunol 1998; 10 (11): 1725.

145) Fischer GF, Fae I, Frey E, Mayr WR. HLA-A*02172* adds to the heterogeneity of HLA-A*02 alleles. Tissue Antigens 1998; 51 (3): 312.

146) Reiter E, Keil F, Brugger S, Kalhs P, Rabitsch W, Hinterberger W, Fischer G, Rosenmayr A, Haas O, Volc B, Lechner K, Greinix HT. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia. Bone Marrow Transplant 1997; 19 (12): 1191.

147) Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Fae I, Waclavicek M, Stockl J, Scheinecker C, Vidicki T, Aschauer H, Johnson JP, Knapp W. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. J Immunol 1997; 158 (5): 2107.

148) Fischer GF, Broer E, Fae I, Leitner D, Mayr WR. Nucleotide sequence analysis of an HLA-B47 variant (HLA-B*4702). Tissue Antigens 1997; 49 (5): 540.

149) Schenk S, Breiteneder H, Susani M, Najafian N, Laffer S, Duchene M, Valenta R, Fischer G, Scheiner O, Kraft D, Ebner C. T cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense). Crossreactivity with group I allergens of different grasses. Adv Exp Med Biol 1996; 409: 141.

150) Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, Jouvin MH, Schmitt-Egenolf M, Kraft D, Kinet JP, Stingl G. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 1996; 157 (2): 607.

151) Legler TJ, Kohler M, Mayr WR, Panzer S, Ohto H, Fischer GF. Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Transfusion 1996; 36 (5): 426.

152) Greinix HT, Keil F, Brugger SA, Reiter E, Linkesch W, Lechner K, Schneider B, Dieckmann KU, Fischer G, Schwarzinger I, Haas O, Hinterberger W, Mannhalter C, Geissler K, Hocker P, Jager U, Kalhs P. Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. Ann Hematol 1996; 72 (2): 53.

153) Fischer GF, Fae I, Moser S, Petrasek M, Bassler HM, Menzel GR, Mayr WR. Ligation based HLA-B*27 typing. Tissue Antigens 1996; 48 (3): 148.

154) Dunky A, Neumuller J, Hubner C, Fischer GF, Bayer PM, Wagner E, Schwartz DW, Mayr WR. HLA-B27 determination using serological methods. A comparison of enzyme immunoassay and a microlymphocytotoxic test with flow cytometry and a molecular biological assay. Rheumatol Int 1996; 16 (3): 95.

155) Breiteneder H, Friedl-Hajek R, Ebner C, Schenk S, Fischer G, Kraft D, Scheiner O. Sequence comparisons of the CDR3 hyper-variable loops of human T cell receptors specific for three major T cell epitopes of the birch pollen allergen Bet v 1. Mol Immunol 1996; 33 (13): 1039.

156) Smrzka OW, Fae I, Stoger R, Kurzbauer R, Fischer GF, Henn T, Weith A, Barlow DP. Conservation of a maternal-specific methylation signal at the human IGF2R locus. Hum Mol Genet 1995; 4 (10): 1945.

157) Schenk S, Breiteneder H, Susani M, Najafian N, Laffer S, Duchene M, Valenta R, Fischer G, Scheiner O, Kraft D, et al. T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T- cell epitopes within grass group I allergens. J Allergy Clin Immunol 1995; 96 (6 Pt 1): 986.

158) Panzer S, Fischer G. Neonatal thrombocytopenia in HLA-DR,-DQ,-DO-typed mother due to a rare anti-HPA 1b (PLA2) (Zwb) fetomaternal immunization [letter; comment]. Vox Sang 1995; 68 (4): 258.

159) Panzer S, Auerbach L, Cechova E, Fischer G, Holensteiner A, Kitl EM, Mayr WR, Putz M, Wagenbichler P, Walchshofer S. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995; 90 (3): 655.

160) Fischer GF, Fae I, Petrasek M, Moser S. A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and -DQB 1 alleles. Vox Sang 1995; 69 (4): 328.

161) Fischer GF, Fae I, Petrasek M, Haas H, Mayr WR. An HLA-DR11 variant (HLA-DRB1*1115) segregating in a family of Turkish origin. Tissue Antigens 1995; 45 (2): 143.

162) Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW, Hoffmann K, Szepfalusi Z, Scheiner O, Kraft D. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995; 154 (4): 1932.

163) Breiteneder H, Scheiner O, Hajek R, Hulla W, Huttinger R, Fischer G, Kraft D, Ebner C. Diversity of TCRAV and TCRBV sequences used by human T-cell clones specific for a minimal epitope of Bet v 1, the major birch pollen allergen. Immunogenetics 1995; 42 (1): 53.

164) Berger J, Bernheimer H, Fae I, Braun A, Roscher A, Molzer B, Fischer G. Association of X-linked adrenoleukodystrophy with HLA DRB1 alleles. Biochem Biophys Res Commun 1995; 216 (2): 447.

165) Schenk S, Hoffmann-Sommergruber K, Breiteneder H, Ferreira F, Fischer G, Scheiner O, Kraft D, Ebner C. Four recombinant isoforms of Cor a 1, the major allergen of hazel pollen, show different reactivities with allergen-specific T-lymphocyte clones. Eur J Biochem 1994; 224 (2): 717.

166) Fischer GF, Pickl WF, Fae I, Anegg B, Milota S, Volc-Platzer B. Association between chronic cutaneous lupus erythematosus and HLA class II alleles. Hum Immunol 1994; 41 (4): 280.

167) Weisman LE, Cruess DF, Fischer GW. Standard versus hyperimmune intravenous immunoglobulin in preventing or treating neonatal bacterial infections. Clin Perinatol 1993; 20 (1): 211.

168) Volc-Platzer B, Anegg B, Milota S, Pickl W, Fischer G. Accumulation of gamma delta T cells in chronic cutaneous lupus erythematosus. J Invest Dermatol 1993; 100 (1): 84S.

169) Pickl WF, Fischer GF, Fae I, Kolarz G, Scherak O. HLA-DR1-positive patients suffering from rheumatoid arthritis are at high risk for developing mucocutaneous side effects upon gold therapy. Hum Immunol 1993; 38 (2): 127.

170) Pickl WF, Fae I, Fischer GF. Detection of established and novel alleles of the HLA-DPB1 locus by PCR- SSO. Vox Sang 1993; 65 (4): 316.

171) Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D, et al. Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation 1993; 55 (4): 782.

172) Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer G, Fae I, Bignon JD, et al. DNA typing of 3500 cadaver kidney transplants does not confirm the "DR6 effect". Transplant Proc 1993; 25 (1 Pt 1): 207.

173) Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Fischer G, Fae I, Middleton D, Savage D, Bignon JD, et al. DNA HLA-DR typing results of 4000 kidney transplants. Transplantation 1993; 55 (4): 778.

174) Fischer GF, Fae I, Pickl WF. The HLA-DRB6*0201 allele of a pseudogene commonly associated with HLA- DR2 specificities is present in an HLA-DRB1*0101-DRB5*0101 haplotype. Immunogenetics 1993; 37 (4): 285.

175) Mytilineos J, Scherer S, Trejaut J, Dunckley H, Chapman J, Fischer G, Fae I, Middleton D, Savage D, Bignon JD, et al. Analysis of discrepancies between serologic and DNA-RFLP typing for HLA- DR in kidney graft recipients. Transplant Proc 1992; 24 (6): 2478.

176) Maurer D, Fischer GF, Fae I, Majdic O, Stuhlmeier K, Von Jeney N, Holter W, Knapp W. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992; 148 (12): 3700.

177) Fischer GF, Pickl WF, Fae I, Ebner C, Ferreira F, Breiteneder H, Vikoukal E, Scheiner O, Kraft D. Association between IgE response against Bet v I, the major allergen of birch pollen, and HLA-DRB alleles. Hum Immunol 1992; 33 (4): 259.

178) Fischer GF, Fae I, Pickl WF. Distribution of polymorphic HLA-DR and -DQ alleles as determined by restriction fragment length polymorphism analysis in an Austrian population. Vox Sang 1992; 62 (4): 236.

179) Fischer GF, Fae I, Dub E, Pickl WF. Analysis of the gene polymorphism of ABO blood group specific transferases helps diagnosis of acquired B status. Vox Sang 1992; 62 (2): 113.

180) Dennig D, Lam C, Fischer G, Scharf M, Knapp W. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates superoxide anion and hydrogen peroxide production in human neutrophils. J Hematother 1992; 1 (3): 261.

181) Smrzka OW, Fae I, Pickl WF, Fischer GF. HLA-DRB3 typing by restriction digestion of locus-specific amplified DNA. Tissue Antigens 1991; 37 (5): 205.

182) Pickl WF, Fischer GF, Fae I, Speiser P. [Identification of an old frozen alcohol blood sample using a genetic probe technique]. Wien Klin Wochenschr 1991; 103 (5): 155.

183) Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer O, Bignon JD, et al. Survival of DNA HLA-DR typed and matched cadaver kidney transplants. The Collaborative Transplant Study. Lancet 1991; 338 (8765): 461.

184) Fischer GF, Pickl WF, Fae I, Pausch V, Speiser P. Elucidation of apparent non-maternity with DNA probes detecting highly polymorphic single locus systems. Vox Sang 1991; 60 (3): 181.

185) Fischer GF, Fae I, Valent P, Pickl WF. [The use of highly polymorphic DNA systems in the demonstration of mixed chimerism following bone marrow transplantation]. Wien Klin Wochenschr 1991; 103 (5): 152.

186) Maurer D, Holter W, Majdic O, Fischer GF, Knapp W. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol 1990; 20 (12): 2679.

187) Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990; 144 (2): 638.

188) Fischer G, Speiser P. [Assessment of apparent non-maternity using individual specific gene probes]. Wien Klin Wochenschr 1990; 102 (10): 309.

189) Fischer GF, Holter W, Majdic O, Cragoe EJ, Jr., Knapp W. T cell stimulation via CD2 molecules is regularly accompanied by an increase in cytoplasmic pH. Different effects of lectins and CD3 antibodies. J Immunol 1988; 141 (2): 404.

190) Holter W, Fischer GF, Majdic O, Stockinger H, Knapp W. T cell stimulation via the erythrocyte receptor. Synergism between monoclonal antibodies and phorbol myristate acetate without changes of free cytoplasmic Ca++ levels. J Exp Med 1986; 163 (3): 654.

Extended Abstracts, Letters

1) Tiercy JM, Fischer G, Setterholm M. Quality control for registry HLA data. Tissue Antigens 2007; 69 Suppl 1: 13.

2) Fischer G. Immunogenetic selection of donors for haematopoietic stem cell transplantation: an approach. Transpl Immunol 2002; 10 (2-3): 223.

3) Fischer G, Kreuzer D, Beer U, Gleissner B, Wasilewski K, Fae I. The sixth quality control exercise of the Central European tissue typing laboratories. Bone Marrow Transplant 1998; 22 Suppl 4: S14.

4) Fischer GF. Molecular genetics of HLA. Vox Sang 2000; 78 (Suppl 2): 261.

5) Panzer S & Fischer G: Neonatal thrombocytopenia in HLA-DR,-DQ,-DP-typed mother due to a rare anti-HPA 1b (PLA2) (Zwb) fetomaternal immunization

Vox Sang. 68: 258 1995

6) Mytilineos J, Scherer S, Trejaut J, Dunckley H, Chapman J, Fischer G, Faé I, Middleton D, Savage D, Bignon JD, Bensa JC, Noreen H, Albert E, Schwarz V, Albrecht G & Opelz G: Analysis of discrepancies between serologic and DNA-RFLP typing for HLA- DR in kidney graft recipients

Transplantation Proc. 24:2478-2479, 1992

7) Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer GF, Bignon JD, Bensa JC, Albert E, & Noreen H, for the Collaborative Study : DNA typing: an important step forward, Transplant International in press

8) Opelz G, Scherer S, Mytilineos J, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer GF, Bignon JD, Bensa JC, Albert E & Noreen H, for the Collaborative Transplant Study: Analysis of HLA matching in renal transplantation based on DNA class II typing. in HLA 1991. Tsuji et al. (eds.), Oxford University Press 1992

9) Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer G, Faé I, Bignon JD, Bensa JC, Albrecht G, Schwarz V & Opelz G: DNA typing of 3500 cadaver kidney transplants does not confirm the "DR6 effect". Transplant Proc. 25:207-209 1992

10) Fischer G& Speiser P: Abklärung einer scheinbaren Nichtmutterschaft mittels individualspezifischer GensondenWien. klin. Wochensch. 102: 309 1990

11) Knapp W, GF Fischer , Holter W, Cragoe jr. EJ & Majdic O: Inhibition of the Na+/proton antiporter with the amiloride analogue 5-(N-methyl-N-isobutyl)amiloride (MIA) leads to superinduction of T cell proliferation induced via the alternate (CD2) pathway, Ann. N. Y. Acad. Sci. 546:216 1989

12) Fischer GF, Kreuzer D, Beer U, Gleißner B, Wasilewski K & Faé I: The sixth Quality Control Exercise of the Central European tissue typing laboratories. Bone Marrow Transplant. (Suppl 4): 14-16 1998

13) Rabitsch W, Reiter E, Keil F, Malzer R, Leitner G, Fischer G, Dieckmann K, Kalhs P, Lechner K & Greinix H T: Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies. Bone Marrow Transplant. (Suppl 4): 49-51 1998

14) Greinix H T, Reiter E, Schulenburg A, Keil F, Lechner K, Fischer G, Rosenmayr A, Leitner G & Kalhs P: Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. Bone Marrow Transplant. (Suppl 4): 53-55 1998

15) Reiter E, Greinix H T, Brugger S, Keil F, Rabitsch W, Mannhalter C, Schwarzinger I, Hoecker P, Fischer G, Dieckmann K, Hinterberger W, Linkesch W, Schneider W, Lechner K & Kalhs P:Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 22(Suppl 4): 86-88 1998

Books

1) Knapp, W, Majdic O, H. Stockinger, Köller U, Bettelheim P, Fischer GF, Skrobal A, & Lutz D: Analytik und Manipulation humaner Zellen mit monoklonalen Antikörpern. in: Biotechnologie von heute. L. Janszky ed., OMIKK Verlag Budapest, P 551987

2) Knapp, W, Holter W, Majdic O, Stockinger H, Fischer GF, Skrobal A: Membrane structures involved in human T cell activation. in: Lectures and Symposia 14 th Int. Cancer Congr. Vol 2: Molecular Biology and Differentiation of Cancer Cells. Lapis/Eckhardt Eds., Karger Verlag, Basel/Academiai Kladò Budapest pp 267-274 1987

3) Fischer GF, Ingrid Faé & Elisabeth Gschwantler: Flow cytometrische Analyse verschiedener Rh-Phänotypen. in: Festschrift zum 65. Geburtstag Prof. Arndt Hanser, Fresenius 1988 pp 7-12

4) Fischer GF, Majdic O & Knapp W: Molecular cytology of granulocyte activation. in: Genotypic, Phenotypic and Functional Aspects of Hematopoiesis. Grignani F., Martelli M.F. and Mason D, eds, Raven Press, N.Y. pp 81-85 1987

5) Fischer GF, Majdic O & Knapp W: Cytological analysis of functional alterations in granulocytes in: New Frontiers in Cytology. K. Goerttler et al., eds., pp 32-36 1988

6) Speiser P unter Mitarbeit von Vilma Pausch, Winter P, Schwartz D, Hajek-Rosenmayer A & Fischer GF: Molekularbiologische Methoden in der Blutgruppenserologie. in: Laboratoriumsdiagnostik.Herausgegeben von Erwin Deutsch, Georg Geyer und Rudolf Wenger (eds.) Schering 1990

7) Fischer G& Mayr WR: Das HLA System. in Transfusionsmedizin. Herausgegeben von Christian Mueller-Eckhardt und Volker Kiefel (eds) Springer 2010

Education

• 2011 - MBA in 'Health Care Management', at the Danube University Krems
• 2010 - Habilitation (venia docendi) in Blood Group Serology & Transfusion Medicine, Medical University of Vienna, Vienna, Austria
• 2004 - Specialization in Blood Group Serology & Transfusion Medicine
• 1997 - Habilitation (venia docendi) in Immunology, Medical University of Vienna, Vienna, Austria
• 1996 - Specialization in Immunology
• 1980-1986 - Medical School, MD, Medical University of Vienna, Vienna, Austria

Positions and Academic Milestones

• Since 2019 - Member of the Commission for curricular development of the Danube University Krems
• 2018- 2019 - Member of the Senate of the Danube University Krems
• Since 2016 - Coordinator of the PhD programme Regenerative Medicine, Danube University Krems, Krems, Austria
• Since 2013 - Full Professor for Tissue and Organ Replacement, Center for Biomedical Technology, Danube University Krems, Krems, Austria
• 2011–2013 - Vice-Curriculum Director, Dental University Vienna, Vienna, Austria
• 1999–2013 - Group Leader Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
• 1997–1999 - Internship and Residency, Vienna Hospital Unions, Vienna, Austria
• Since 1997 - Faculty Member and Instructor in Pathology, Department of Pathology, Harvard Medical School, Boston MA, USA
• 1994–1997 - Post-doctoral Fellow in Experimental Pathology, Department of Pathology, Harvard Medical School, Boston MA, USA
• 1988–1994 - Post-doctoral Fellow in Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria

Academic Publications (selection of 5 most important studies)

• Kocsis Á, Pasztorek M, Rossmanith E, Djinovic Z, Mayr T, Spitz S, Zirath H, Ertl P, Fischer MB. Dependence of mitochondrial function on the filamentous actin cytoskeleton in cultured mesenchymal stem cells treated with cytochalasin B. J Biosci Bioeng. 2021. doi: 10.1016/j.jbiosc.2021.05.010.
• Rüger BM, Buchacher T, Dauber EM, Pasztorek M, Uhrin P, Fischer MB, Breuss JM, Leitner GC. De novo Vessel Formation Through Cross-Talk of Blood-Derived Cells and Mesenchymal Stromal Cells in the Absence of Pre-existing Vascular Structures. Front Bioeng Biotechnol. 2020. doi:10.3389/fbioe.2020.602210.
• Pasztorek M, Rossmanith E, Mayr C, Hauser F, Jacak J, Ebner A, Weber V, Fischer MB. Influence of Platelet Lysate on 2D and 3D Amniotic Mesenchymal Stem Cell Cultures. Front Bioeng Biotechnol. 2019 Nov 15;7:338. doi: 10.3389/fbioe.2019.00338.
• Thaler B, Hohensinner PJ, Baumgartner J, Haider P, Krychtiuk KA, Schörgenhofer C, Jilma B, Hell L, Fischer MB, Huber K, Hengstenberg C, Speidl WS, Wojta J. Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo. Thromb Haemost. 2019 Sep;119(9):1394-1402. doi: 10.1055/s-0039-1692219.
• Thaler B, Baik N, Hohensinner PJ, Baumgartner J, Panzenböck A, Stojkovic S, Demyanets S, Huk I, Rega-Kaun G, Kaun C, Prager M, Fischer MB, Huber K, Speidl WS, Parmer RJ, Miles LA, Wojta J. Differential expression of Plg-RKT and its effects on migration of proinflammatory monocyte and macrophage subsets. Blood. 2019 Aug 8;134(6):561-567. doi: 10.1182/blood.2018850420.

Research interests

MBF’s research interests focus on regenerative medicine with particular emphasis of the role of inflammation on healing, on stem cell research on mesenchymal stem cells, clinical immunology including changes in T cell subsets during inflammation and transplant immunology and blood banking. He serves as reviewer in multiple high ranked international journals, is a member of several national and international societies in the field of immunology, transfusion medicine, cell-therapy and stem cell research and is connected in several international networks.  He published more than 150 peer reviewed publications including articles in Immunity, Science, NEJM, Blood and Frontiers in Immunology.

Additional research achievements

Academic Awards

2020 - 'Best Paper of the month', Medical University of Vienna

2006 - 'Best Paper of the month/year', Medical University of Vienna

2007 - ‘Best Dissertation' of the Medical University of Vienna – Student David Holleman

1993 - ‘Erwin Schrödinger’ stipend of the FWF

• klinische Transfusionsmedizin
• Herstellungsleitung Blutkomponenten (Thrombozytenkonzentrate, Serum-Augentropfen)

Positionen und Funktionen

• seit 10/2021 Herstellungsleitung Blutprodukte und Arzneimittel (QS-VO Blut und AMG)

• seit 10/2021 Stv. Projektleitung Stammzellspende MedUni Wien

• seit 04/2021 Sachkundige Person (AMG Qualified Person)

• seit 2013 Risikomanagerin

• seit 2009 Interne Auditorin

• seit 2007 Qualitätsbeauftragte

• seit 1994 Strahlenschutzbeauftragte

Ausbildung

• 2021 Qualified Person

• 2013 Ausbildung Risikomanagement

• 2009 Ausbildung Interne Auditorin

• 2007 Ausbildung Qualitätsmanagement

• 2000 Fachärztin für Blutgruppenserologie und Transfusionsmedizin

• 1994–2000 Fachärzt:innenausbildung Blutgruppenserologie und Transfusionsmedizin Medizinische Universität Wien

• 1993 Notärztin

• 1993 Ärztin für Allgemeinmedizin mit ius practicandi

• 1990–1993 Ausbildung Ärztin für Allgemeinmedizin LKH Oberwart

• klinische Transfusionsmedizin
• Patient Blood Management
• transfusionsmedizinische Schwangerschaftsbetreuung

Positionen und Funktionen

• seit 10/2022 Leitung Patient Blood Management
• seit 10/2021 Stv. Herstellungsleitung Blutprodukte und Arzneimittel
• seit 07/2021 Stv. Strahlenschutzbeauftragte
• seit 2018 Mitarbeit am Projekt Stammzellspende MedUni Wien
• seit 2019 Sachkundige Person (AMG Qualified Person)
• seit 2015 Fachärztin für Blutgruppenserologie und Transfusionsmedizin

Ausbildung

• 2021 Ausbildung Strahlenschutzbeauftragte
• 2020 Ausbildung Qualified Person
• 2018 Notärztin (ÖÄK-Diplom)
• 2015 Fachärztin für Blutgruppenserologie und Transfusionsmedizin
• 2004–2015 Fachärzt:innenausbildung für Blutgruppenserologie und Transfusionsmedizin an der Medizinischen Universität Wien
• 1999–2004 Studium der Humanmedizin an der Medizinischen Universität Wien
• 1999 Abschluss an der Technischen Universität Wien

• Leitung Erythrozytenlabor und Hämogenetik

• Leitung Granulozytenlabor

• Immunhämatologie
• Granulozytenimmunologie
• Hämogenetik

• Immunhämatologie
• Hämogenetik
• Allo- und Autoimmunisierung
• Granulozytenimmunologie
• Entzündungsmechanismen
• Transplantationsimmunologie
• Qualitätsmanagement
• universitäre Lehre

• Leitung Blutproduktausgabe und Depot der Universitätsklinik für Transfusionsmedizin und Zelltherapie
• Leitung Lehre Transfusionsmedizin an der Universitätsklinik für Transfusionsmedizin und Zelltherapie der Medizinischen Universität Wien und AKH Wien
• Informationstechnologie

Berufserfahrung

• Seit 2005 Leiter der Lehre Transfusionsmedizin der Universitätsklinik für Transfusionsmedizin und Zelltherapie der Medizinischen Universität Wien
• Seit 2002 Außerordentlicher Professor an der Universitätsklinik für Transfusionsmedizin und Zelltherapie der Medizinischen Universität Wien
• Seit 2001 Leiter des Blutdepots am AKH Wien
• Seit 2001 Venia docendi für Blutgruppenserologie und Transfusionsmedizin
• 1997 Research Fellow an der Abt. f. Transfusionsmedizin der Georg-August Universität Göttingen
• 1997 Facharzt f. Blutgruppenserologie und Transfusionsmedizin
• 1993–2002 Universitätsassistent an der Univ. Klinik f. Blutgruppenserologie und Transfusionsmedizin der Medizinischen Universität Wien
• 1992 Research Fellow am Dept of Anesthesia der University of California San Francisco (UCSF)
• 1991–1993 Assistentsarzt an der Internen Abt., KH Floridsdorf
• 1991 Ius practicandi
• 1989–1992 Sekundararzt bei der Gemeinde Wien
• 1989 Universitätsassistent an der Univ. Klinik f. Anästhesie und Intensivmedizin, Universität Wien
• 1988 Gastarzt an der Univ. Klinik f. Anästhesie und Intensivmedizin, AKH Wien
• 1986–1988 Präsenzdienst mit angeschlossener Ausbildung zum Heeresanästhesisten

Schul- und Berufsbildung

• 2015 abgeschlossene Ausbildung „MLS Medizinrecht“ an der Donau Universität Krems

• 2011 abgeschlossene Ausbildung „MBA Health Care Medicine“ an der WU Wien

• 2002 Außerordentlicher Professor f. Blutgruppenserologie und Transfusionsmedizin

• 2001 Venia Docendi f. Blutgruppenserologie und Transfusionsmedizin

• 1986 Promotion zum Dr. med. univ an der Medizinischen Fakultät der Universität Wien

• 1979 Matura am BG und BRG Wien XXI

Bezeichnung der erworbenen Qualifikation

Ao.Univ.-Prof. Dr. med. univ. Martin Kurz, MBA, MLS

Sonstige Fähigkeiten und Kompetenzen

• Leitung des Bereichs „Transfusionsmedizinische Lehre“ der Univ. Klinik f. Blutgruppenserologie und Transfusionsmedizin der Medizinischen Universität Wien

• Abgeschlossene Ausbildung zum Auditor-Anwärter nach ISO 9000/2001

• Abgeschlossene Masterausbildung in Health Care Management (MBA)

• Abgeschlossene Masterausbildung in Medizinrecht (MLS)

Mitgliedschaften

• Österreichische Gesellschaft für Blutgruppenserologie und Transfusionsmedizin (ÖGBT)

• American Association of Blood Banks (AABB)

• Spezielle Immunhämatologie
• Schwangerschaft, Pränataldiagnostik und Perinatale Transfusionsmedizin
• Autoimmunerkrankungen
• Thrombozytenimmunologie und -funktionsdiagnostik
• Transfusionsmedizinische Infektionsdiagnostik
• Genetik
• Informationstechnologie

Positionen und Funktionen

• 1996–laufend Ao. Univ. Professor an der Universitätsklinik für Transfusionsmedizin und Zelltherapie 
• 2020–laufend Mitglied der Ethikkommission des Österreichischen Roten Kreuzes
• 2017–laufend Mitglied der Blutkommission des Bundesministeriums für Soziales, Gesundheit, Pflege und Konsumentenschutz
• 2013–laufend Mitglied des Vorstands der Österreichischen Gesellschaft für Blutgruppenserologie, Transfusionsmedizin, Regenerative Medizin und Immungenetik (ÖGBT)
• 2007–laufend Mitglied der Prüfungskommission Facharztprüfung der Österreichischen Ärztekammer
• 2007–2022 Fachgruppenobmann für Blutgruppenserologie und Transfusionsmedizin an der Ärztekammer für Wien
• 1994–2005 Laborleiter an der Blutspendezentrale des Österreichischen Roten Kreuzes für Wien, Niederösterreich und Burgenland
• 1996 Habilitation („Mikrosatellitenpolymorphismen“)
• Ernennung zum Ao.Univ.Prof., Übernahme in den Bundesdienst
• Anerkennung als Facharzt für Blutgruppenserologie und Transfusionsmedizin

Klinische Ausbildung

• 1992–1996 Assistenzarzt an der Universitätsklinik für Blutgruppenserologie und Transfusionsmedizin
• 1994–2008 Grundwehrdienst, Übernahme in den Kader, Truppenübungen, Abrüstung als Zugsführer
• 1985–1992 Assistenzarzt am Inst.f.Blutgruppenserologie der Universität Wien
• 1984–1985 Studium Datentechnik an der Technischen Universität Wien
• 1979–1985 Studium Humanmedizin an der Universität Wien der Universität Wien (seit 2001 der Medizinischen Universität Wien)

Mitgliedschaften

• ÖGBT (Österreichischen Gesellschaft für Blutgruppenserologie, Transfusionsmedizin, Regenerative Medizin und Immungenetik)

• DGTI (Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie

• EFI (European Federation for Immunogenetics)

Positionen und Funktionen

• Seit 2014 an der Universitätsklinik für Transfusionsmedizin und Zelltherapie am AKH Wien, seit 2017 als Facharzt für Blutgruppenserologie und Transfusionsmedizin
• Stv. Leitung Blutdepot
• Stv. Leitung Lehre Transfusionsmedizin

Bereiche

• klinische Transfusionsmedizin, Erythrozytenimmunologie, Informationstechnologie

 

Publikationen (»vollständige Publikationsliste von Alexander Tolios)

• Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. Mohr T, Katz S, Paulitschke V, Aizarani N, Tolios A. Cancers (Basel). 2021 Apr 7;13(8):1768. doi: 10.3390/cancers13081768.
• Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Drug Resist Updat. 2020 Jan;48:100662. doi: 10.1016/j.drup.2019.100662. Epub 2019 Oct 18.
• Thrombomodulin in patients with mild to moderate bleeding tendency. Mehic D, Tolios A, Hofer S, Ay C, Haslacher H, Downes K, Haimel M, Pabinger I, Gebhart J. Haemophilia. 2021 Nov;27(6):1028-1036. doi: 10.1111/hae.14433. Epub 2021 Oct 10.
• Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. Mehic D, Tolios A, Hofer S, Ay C, Haslacher H, Rejtö J, Ouwehand WH, Downes K, Haimel M, Pabinger I, Gebhart J. Blood Adv. 2021 Jan 26;5(2):391-398. doi: 10.1182/bloodadvances.2020003464.
• Preanalytical Conditions and DNA Isolation Methods Affect Telomere Length Quantification in Whole Blood. Tolios A, Teupser D, Holdt LM. PLoS One. 2015 Dec 4;10(12):e0143889. doi: 10.1371/journal.pone.0143889. ECollection 2015.

Clinical Position

• Physician/Specialist ("Facharzt") in the field of Transfusion Medicine and Laboratory Medicine
• Interim head of the platelet immunology and platelet function lab
• Head of the transfusion medicine clinical routine laboratory
• Trainee in the HLA/transplant immunology lab

Professional Training

• 10/2015 – 09/2023: Transfusion Medicine resident and research fellow, Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria
• 07/2020 – 06/2021: Research fellow at the Institute of Vascular Biology and Thrombosis Research as well as the Institute for Artificial Intelligence and Decision Support, Medical University of Vienna, Vienna, Austria
• 04/2017 – 09/2017: Laboratory Medicine resident and research fellow, Institute of Clinical Chemistry and Laboratory Diagnostics, Heinrich Heine University, Duesseldorf, Germany
• 07/2013 – 09/2015: Laboratory Medicine resident and research fellow, Institute of Laboratory Medicine,  Ludwig Maximilian University, Munich, Germany
• 10/2011 – 06/2013: Research fellow and Internal Medicine resident, Department of Physiology and Department of Internal Medicine, Eberhard Karls University, Tuebingen, Germany

Research interests

• Bioinformatics, biostatistics/data science and predictive modeling/machine learning
• Immunohematology and immunogenetic diagnostics
• Methods in molecular biology and genetics and laboratory diagnostic techniques
• Platelet physiology and biochemistry

Acquired grants

• Medizinisch-Wissenschaftlicher Fond des Bürgermeisters der Bundeshauptstadt Wien (Project number 22090) for the Project "Analyse von DNA-Methylierung zur Gewebe-Zuordnung und Tumordetektion", granted 06/2022
• Austrian Academy of Science for the Project "Detecting Cancer of Unknown Primary by Analysis of Epigenetic Markers", granted 09/2022

• Leitung Therapeutische Apheresen

• Leitung Zell- & Gewebeentnahmeeinrichtung und Gewebebank

• Herstellungsleitung ATMP

• Therapeutische Apheresen
• Stammzellmobilisierung & Stammzellsammlung
• Therapie mit Immuneffektorzellen inkl. CAR-T Zellen

• Optimierung der Stammzellmobilisation
• extrakorporale Photopherese in der Therapie der GvHD und Organtransplantation
• CAR-T Zellen

Original papers

• 102. Infanti L, Leitner G, Moe MK, Pehlic V, Benkert P, Cattaneo M, Holbro A, Passweg J, Worel N, Buser A. Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment. Blood Cells Mol Dis. 2022 Jun 26;97:102689. doi: 10.1016/j.bcmd.2022.102689. PMID: 35780678
• 101. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.Haematologica. 2022 May 1;107(5):1045-1053.
• 100. Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M. Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy.Transplant Cell Ther. 2022 Apr 10:S2666-6367(22)01198-8. doi: 10.1016/j.jtct.2022.04.003. PMID: 35413459.
• 99. Gökler J, Aliabadi-Zuckermann A, Zuckermann A, Osorio E, Knobler R, Moayedifar R, Angleitner P, Leitner G, Laufer G, Worel N. Extracorporeal Photopheresis With Low-Dose Immunosuppression in High-Risk Heart Transplant Patients-A Pilot Study.Transpl Int. 2022 Mar 23;35:10320. doi: 10.3389/ti.2022.10320. eCollection 2022. PMID: 35401042.
• 98. Porpaczy E, Wohlfarth P, Königsbrügge O, Rabitsch W, Skrabs C, Staber P, Worel N, Müllauer L, Simonitsch-Klupp I, Kornauth C, Rohrbeck J, Jaeger U, Schiefer AI. Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers (Basel). 2021 Nov 9;13(22):5592.
• 97. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1403-1415.
• 96. Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT; Worldwide Network for Blood & Marrow Transplantation. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transplant Cell Ther. 2021 Mar;27(3):270.e1-270.e6. Epub 2020 Dec 15.
• 95. Oberbauer R, Edinger M, Berlakovich G, Kalhs P, Worel N, Heinze G, Wolzt M, Lion T, Wekerle T. A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001).Front Med (Lausanne). 2021 Jan 27;7:634260. eCollection 2020.
• 94. Benazzo, A., Worel, N., Schwarz, S., Just, U., Nechay, A., Lambers, C., Böhmig, G., Fischer, G.b, Koren, D., Muraközy, G., Knobler, R., Klepetko, W., Hoetzenecker, K., Jaksch, P. Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients. Transfus Med Hemother. 2020 Jun;47(3):205-213
• 93. Goekler, J., Zuckermann, A., Worel, N., Ceran, E., Kaiser, P., Neuber, N., Laufer, G., Aliabadi-Zuckermann, A. Extracorporeal Photopheresis Immediately after Heart Transplantation in High Risk Patients. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation. 2020, 39(4), pp. S229.
• 92. Greinix, H.T., Attarbaschi, A., Girschikofsky, M., Greil, R., Holter, W., Neumeister, P., Peters, C., Petzer, A., Rudzki, J., Schlenke, P., Schmitt, C.A., Schwinger, W., Wolf, D., Worel, N., Jaeger, U Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. Memo - Magazine of European Medical Oncology. 2020;13(1), pp. 27-31
• 91. Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020 Apr;55(4):681-694.
• 90. Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018 Oct 20;18(1):1008.
• 89. Worel N, Lehner E, Führer H, Kalhs P, Rabitsch W, Mitterbauer M, Hopfinger G, Greinix HT. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfusion. 2018 Apr;58(4):1045-1053.
• 88. Holbro A, Baldomero H, Lanza F, Chabannon C, Snowden JA, Buser A, Infanti L, Worel N, Sureda A, Badoglio M, Passweg J, Bonini C; Cellular Therapy & Immunobiology Working Party of the European Society for Blood & Marrow Transplantation (EBMT) and the Joint Accreditation Committee International Society for Cellular Therapy & EBMT (JACIE). Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy. 2018 Mar;20(3):453-460.
• 87. Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. Vox Sang. 2017 Oct;112(7):e48-e68.
• 86. Morton S, Stanworth S, Lozano M, Harrison SJ, Hong FS, Dennington P, McQuilten Z, Worel N, Compernolle V, Kutner JM, Yokoyama APH, Nahirniak S, Germain M, Hume H, Robitaille N, Wilson A, Tinmouth A, Massey E, Boulat C, Woimant G, Tiberghien P, Schulze TJ, Bux J, Pierelli L, Ballester C, Netelenbos T, West KA, Conry-Cantilena C, Eder A, Haley NR, Yazer M, Triulzi D. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sang. 2017 Oct;112(7):680-683.
• 85. Worel N, Frank N, Frech C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017 Sep;57(9):2206-2215
• 84. Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C, Mohty M. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017 Oct;52(10):1367-1371.
• 83. Worel N, Fritsch G, Agis H, Böhm A, Engelich G, Leitner GC, Geissler K, Gleixner K, Kalhs P, Buxhofer-Ausch V, Keil F, Kopetzky G, Mayr V, Rabitsch W, Reisner R, Rosskopf K, Ruckser R, Zoghlami C, Zojer N, Greinix HT.Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher. 2017 Aug;32(4):224-234.
• 82. Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, Frech C, Fritsch G. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant. 2016 Aug;51(8):1093-100.
• 81. Fritsch G, Frank N, Dmytrus J, Frech C, Pichler H, Witt V, Geyeregger R, Scharner D, Trbojevic D, Zipperer E, Printz D, Worel N. Relevance of flow cytometric enumeration of post-thaw leucocytes: influence of temperature during cell staining on viable cell recovery. Vox Sang. 2016 Aug;111(2):187-96.
• 80. Bojic M, Worel N, Sperr WR, Schellongowski P, Wohlfarth P, Schwarzinger I, Mitterbauer-Hohendanner G, Fischer G, Dieckmann KU, Lamm W, Leiner M, Schulenburg A, Mitterbauer M, Greinix HT, Kalhs P, Rabitsch W. Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation. Oncology. 2016;90(3):160-6.
• 79. Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90.
• 78. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103
• 77. Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher MA, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Leitner G, Netelenbos T, Niederwieser D, van Walraven SM, Rocha V, Torosian T, Vergueiro C, Weisdorf D, Yabe H, Halter JP. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015 Dec;21(12):2052-60.
• 76. Lamm W, Wohlfarth P, Bojic M, Schörgenhofer C, Drach J, Gisslinger H, Worel N, Schiefer A, Schulenburg A, Agis H, Kalhs P, Greinix HT, Schellongowski P, Rabitsch W. Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. Oncology. 2015;89(4):196-204
• 75. Leitner GC, Kolovratova V, Horvath M, Worel N. Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Transfusion. 2015 May;55(5):991-5.
• 74. Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014 Mar;16(3):289-97.
• 73. Boehm A, Sperr WR, Kalhs P, Greinix H, Valent P, Worel N, Kainz A, Mitterbauer M, Bojic M, Rabitsch W. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wien Klin Wochenschr. 2014 Jan;126(1-2):23-9.
• 72. Repa A, Mayerhofer M, Worel N, Cardona F, Deindl P, Pollak A, Berger A, Haiden N. Blood transfusions using 27 gauge PICC lines: a retrospective clinical study on safety and feasibility. Klin Padiatr. 2014 Jan;226(1):3-7.
• 71. Wohlfarth P, Ullrich R, Staudinger T, Bojic A, Robak O, Hermann A, Lubsczyk B, Worel N, Fuhrmann V, Schoder M, Funovics M, Rabitsch W, Knoebl P, Laczika K, Locker GJ, Sperr WR, Schellongowski P; Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN). Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Crit Care. 2014 Jan 20;18(1):R20.
• 70. Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014 Jul;49(7):865-72.
• 69. Rabitsch W, Böhm A, Bojic M, Schellongowski P, Wöhrer S, Sliwa T, Keil F, Worel N, Greinix H, Hauswirth A, Kalhs P, Jaeger U, Valent P, Sperr WR. Clofarabine/cyclophosphamide for debulking before stem cell transplantation. Eur J Clin Invest. 2014 Aug;44(8):775-83.
• 68. Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica. 2014 Nov;99(11):1746-1752.
• 67. Worel N, Knöbl P, Karanikas G, Fuchs EM, Bojic A, Brodowicz T, Jilma P, Zielinski CC, Köstler WJ, Locker GJ. Hepatic dysfunction contributes to coagulation disturbances in pts undergoing whole body hyperthermia by use of extracorporeal circulation. Int J Artif Organs. 2014 Sep 20;37(9):715-726.
• 66. Leitner GC, Kolovratova V, Horvath M, Worel N. Granulocyte collection using a novel apheresis system eases the procedure and provides concentrates of high quality. Transfusion. 2014 Nov 21
• 65. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D.Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).Bone Marrow Transplant. 2013 Feb;48(2):220-5.
• 64. Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G.Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013 Jul;19(7):1129-33.
• 63. Repa A, Mayerhofer M, Cardona F, Worel N, Deindl P, Pollak A, Berger A, Haiden N. Safety of blood transfusions using 27 gauge neonatal PICC lines: an in vitro study on hemolysis. Klin Padiatr. 2013 Dec;225(7):379-82.
• 62. Hejna M, Birner P, Preusser M, Thallinger CM, Worel N, Asari R, Dolak W, Schmid R, Schoppmann SF, Raderer M. Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. Mol Clin Oncol. 2013 Nov;1(6):1079-1083.
• 61. Worel N, Apperley J, Basak G, Douglas K, Gabriel I, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte R, Mohty M. European Data on Stem Cell Mobilization with Plerixafor in Patients with Non-Hematologic Diseases: An Analysis of the European Consortium of Stem Cell Mobilization. Transfusion. 2012 Nov;52(11):2395-400.
• 60. Auer-Hackenberg, L., Staudinger, T., Bojic, A., Locker, G., Leitner, G.C., Graninger, W., Winkler, S., Ramharter, M., Worel, N. Automated red blood cell exchange as an adjunctive treatment for severe Plasmodium falciparum malaria at the Vienna General Hospital in Austria: A retrospective cohort study. Malaria Journal. 2012;Volume 11,Article number 158.
• 59. Kolovratova V, List J, Worel N, Jilma P, Leitner G. Administration of Prednisolone intravenously or Dexamethason orally in random donors reveals equal results in granulocyte collection: a single centre experience. Vox Sang. 2012 Jul;103(1):75-8.
• 58. Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2012 Aug;47(8):1046-50.
• 57. Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant. 2012 Feb;18(2):314-7.
• 56. Basak GW, Wiktor-Jedrzejczak W, Apperley JF, Douglas KW, Gabriel IH, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant. 2012 Jul;47(7):1003-5.
• 55. Locker GJ, Fuchs EM, Worel N, Bojic A, Heinrich G, Brodowicz T, Clodi M, Funk GC, Knöbl P, Zielinski CC, Köstler WJ. Whole body hyperthermia by extracorporeal circulation in spontaneously breathing sarcoma patients Hemodynamics and oxygen metabolism. Int J Artif Organs. 2011 Nov;34(11):1085-94.
• 54. Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Greinix HT. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2011 Sep 16.
• 53. Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers FW, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontão-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Arvola A, Humpe A, Buwitt-Beckmann U, Wiesneth M, Schauwecker P, Schrezenmeier H, Bönig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey R, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S. Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow). Vox Sang. 2011 Oct;101(3):255-75.
• 52. Boehm A, Rabitsch W, Locker GJ, Worel N, Robak O, Laczika KF, Staudinger T, Bojic A, Siersch V, Valent P, Sperr WR. Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation. Wien Klin Wochenschr. 2011 Jun;123(11-12):354-8.
• 51. Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM, Rao K, Maris M, Pagliuca A, Uberti J, Scheid C, Noppeney R, Cook G, Bokhari SW, Worel N, Mikala G, Masszi T, Taylor R, Treisman J. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant. 2011 Feb 28.
• 50. Boehm A, Walcherberger B, Sperr WR, Wöhrer S, Dieckmann K, Rosenmayr A, Pernicka E, Fischer G, Worel N, Mitterbauer G, Schwarzinger I, Mitterbauer M, Haas OA, Lechner K, Hinterberger W, Valent P, Greinix HT, Rabitsch W, Kalhs P. Improved outcome in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: A single center experience. Biol Blood Marrow Transplant. 2011 Jan;17(1):133-40.
• 49. D’Addio A, Worel N, Motta MR, Rizzi S, Dan E, Taglioli S, Giudice V, Agis H, Kopetzky G, Douglas K, Baccarani M, Lemoli RM. The addition of Plerixafor allows adequate PBSC collection in Multiple Myeloma and Lymphoma patients poor–mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011;46(3):356-63.
• 48. Worel N, Böhm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, Mayr WR, Schwartz D, Greinix HT. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. Transfusion. 2011 Dec 1.
• 47. Greinix HT, Worel N, Knobler R. Role of Extracorporeal Photopheresis (ECP) in the treatment of steroid-refractory acute Graft-versus-Host disease. Biol Blood Marrow Transplant. 2010 Dec;16(12):1747-8.
• 46. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2010 Sep 28
• 45. Leitner GC, Dettke M, List J, Worel N, Weigel G, Fischer MB. Red blood units collected from bone marrow harvests after mononuclear cell selection qualify for autologous use. Vox Sang. 2010 pr;98(3 PT 1):e284-9. Epub 2010 Jan 4.
• 44. Worel N, Panzer S, Reesnik HW, Linkesch W, Dickmeiss E, Fischer-Nielsen A, Hölig K, Stachel D, Zimmermann R, Holter W, Coluccia P, Brilhante D, Watz E, Sigle JP, Gratwohl A, Buser A, Arslan O, Regan F, Edwards M. Transfusion policy in ABO-incompatible allogeneic stem cell transplantation. Vox Sang. 2010;98:455-67.
• 43. Mayerhofer M, Haushofer A, Kyrle PA, Chott A, Müllner C, Quehenberger P, Worel N, Traby L, Eichinger S. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest. 2009;39(9):833-6.
• 42. Kuzmina Z, Greinix HT, Knobler R, Worel N, Kouba M, Weigl R, Körmöczi U, Rottal A, Pohlreich D, Zielinski C, Pickl WF. Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic GVHD. Blood. 2009;114(3):744-6.
• 41. Leitner GC, Baumgartner K, Kalhs P, Biener D, Greinix HT, Hoecker P, Worel N. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study. Bone Marrow Transplant. 2009;43(5):357-63.
• 40. Seidel MG, Minkov M, Witt V, Matthes-Martin S, Pötschger U, Worel N, Leitner G, Stary J, Gadner H, Peters C. Granulocyte transfusions in children and young adults: does the dose matter? J Pediatr Hematol Oncol. 2009;31(3):166-72.
• 39. Boehm A, Sperr WR, Leitner G, Worel N, Oehler L, Jaeger E, Mitterbauer M, Haas OA, Valent P, Kalhs P, Rabitsch W. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38(12):945-52.
• 38. Worel N, Bojic A, Binder M, Jaksch P, Mitterbauer G, Streubel B, Thalhammer F, Staudinger T, Laczika KF, Locker GJ. Catastrophic graft-versus-host disease after lung transplantation proven by PCR-based chimerism analysis. Transpl Int. 2008;21(11):1098-101.
• 37. Worel N, Leitner G, Wagner A, Greinix HT, Höcker P, Kahls P. Therapeutic apheresis in hematopoietic cell transplantation. Turk J Hematol 2008;25:164-71.
• 36. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007;67(4):427-32.
• 35. Schmid, K.E., Worel, N., Höcker, P., Binder, S. Extracorporal rheohaemapheresis for age related macular degeneration: Preliminary experience in 4 patients. Spektrum d. Augenheilkunde. 2007, Volume 21, Issue 4, Pages 240-242
• 34. Leitner GC, Koszik F, Rudnicki T, Buchta C, Worel N, Fischer MB, Schneeberger A, Hoecker P. Apheresis products of the Amicus and the AS.TEC 204 cell separators are comparable with regard to dendritic cells derived from the mononuclear cell collection. Vox Sang. 2007;92(1):37-41.
• 33. Worel N, Greinix HT, Supper V, Leitner G, Mitterbauer M, Rabitsch W, Fischer G, Rosenmayr A, Höcker P, Kalhs P. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion. 2007;47(8):1494-502.
• 32. Worel N, Greinix HT, Leitner G, Mitterbauer M, Rabitsch W, Rosenmayr A, Höcker P, Kalhs P. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci. 2007;36(3):297-304.
• 31. Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr. 2006;118(1-2):49-53.
• 30. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, Mitterbauer M, Rabitsch W, Schulenburg A, Kalhs P. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405-8.
• 29. Buchta C, Dettke M, Funovics PT, Höcker P, Knöbl P, Macher M, Quehenberger P, Treitl C, Worel N. Fibrin sealant produced by the CryoSeal FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting. Vox Sang. 2004; 86(4):257-62.
• 28. Buchta C, Dettke M, Funovics PT, Hirschl AM, Macher M, Worel N, Höcker P. Impact of manufacturing, irradiation and filtration steps to bacterial contamination of autologous fibrin sealant. Biologicals. 2004;32(3):165-9.
• 27. Rabitsch W, Knöbl P, Prinz E, Keil F, Greinix H, Kalhs P, Worel N, Jansen M, Hörl WH, Derfler K. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Bone Marrow Transplant. 2003;32(10):1015-9.
• 26. Kaufmann H, Ackermann J, Greinix H, Nösslinger T, Gisslinger H, Keck A, Ludwig H, Worel N, Kalhs P, Zielinski C, Drach J. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features. Ann Oncol. 2003;14(11):1667-72.
• 25. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A, Mitterbauer M, Mannhalter C, Mayr WR, Schwarzinger I, Höcker P, Lechner K, Greinix HT. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion. 2003;43(8):1153-61.
• 24. Keil F, Prinz E, Moser K, Mannhalter C, Kalhs P, Worel N, Rabitsch W, Schulenburg A, Mitterbauer M, Greinix H. Rapid establishment of long-term culture-initiating cells of donor origin after NMA allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation.2003;76(1):230-6.
• 23. Worel N, Biener D, Kalhs P, Mitterbauer M, Keil F, Schulenburg A, Höcker P, Dieckmann K, Fischer G, Rosenmayr A, Linkesch W, Hinterberger W, Lechner K, Greinix HT. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant. 2002;30(9):619-26.
• 22. Worel N, Greinix HT, Keil F, Mitterbauer M, Lechner K, Fischer G, Mayr W, Höcker P, Kalhs P. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion. 2002;42(10):1293-301.
• 21. Keil F, Prinz E, Kalhs P, Lechner K, Moser K, Schwarzinger I, Jäger U, Fonatsch C, Worel N, Mannhalter C, Rabitsch W, Loidolt H, Schulenburg A, Mitterbauer M, Höcker P, Greinix HT. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia. 2001;15(3):355-61.
• 20. Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Höcker P, Gisslinger H, Lechner K, Kalhs P, Drach J. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol. 2001;80(6):345-8.
• 19. Dettke M, Greinix HT, Kalhs P, Kührer I, Worel N, Höcker P. Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest. Transfusion. 2001;41(5):681-6.
• 18. Worel N, Kurz M, Peters C, Höcker P. Serial granulocytapheresis under daily administration of rHuG-CSF: effects on peripheral blood counts, collection efficiency, and yield. Transfusion. 2001; 41(3):390-5.
• 17. Keil F, Mitterbauer G, Chen X, Haas OA, Kalhs P, Lechner K, Mannhalter C, Moser K, Worel N, Pirc-Danoewinata H, Louda N, Loidolt H, Rabitsch W, Greinix HT. PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR. Transfusion. 2001;41(1):111-6.
• 16. Worel, N., Keil, F., Greinix, H., Kalhs, P., Höcker, P. Delayed massive immune hemolysis after minor ABO incompatible stem cell transplantation. Infusionstherapie und Transfusionsmedizin (from 1992 to 2002, continued as Transfusion Medicine and Hemotherapy); 2001,28(SUPPL. 1), pp. 23.
• 15. Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol. 2000;79(7):374-7.
• 14. Keil, F., Louda, N., Chen, X., Karlik, H., Kalhs, P., Worel, N., Rabitsch, W., Lechner, K., Greinix, H. Expansion of bcr-abl negative progenitor cells in LTBMC by MIP-la, SCF, IL-3 and IL-6. Blood. Volume 96, Issue 11 PART II, 2000, pp 121b.
• 13. Worel, N., Keil, F., Kalhs, P., Biener, D., Mitterbauer, M., Rabitsch, W., Hoecker, P., Lechner, K., Greinix, H. Long term outcome of patients who are alive and in complete remission two years after allogeneic stem cell transplantation. Blood. Volume 96, Issue 11, PART I, 2000, pp. 202a.
• 12. Schulenburg A, Kalhs P, Worel N, Höcker P, Knöbl P, Greinix HT. Immunologic recovery of patients given CD34-selected peripheral blood progenitor cell transplantation for malignant diseases. Bone Marrow Transplant. 2000;25(2):223-4.
• 11. Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knöbl P, Reiter E, Derfler K, Fischer G, Hinterberger W, Höcker P, Kalhs P. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40(5):543-50.
• 10. Reiter E, Greinix HT, Keil F, Brugger S, Rabitsch W, Schulenburg A, Mannhalter C, Schwarzinger I, Worel N, Volc-Platzer B, Fischer G, Dieckmann K, Hinterberger W, Schneider B, Haas OA, Geissler K, Kalhs P. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol. 1999;78(11):507-13.
• 9. Peters C, Minkov M, Matthes-Martin S, Pötschger U, Witt V, Mann G, Höcker P, Worel N, Stary J, Klingebiel T, Gadner H. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol. 1999;106(3):689-96.
• 8. Keil F, Kalhs P, Chen X, Haas OA, Fritsch G, Chott A, Lechner K, Moser K, Ackermann J, Rabitsch W, Worel N, Mannhalter C, Greinix HT. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation. Ann Hematol. 1999;78(8):376-9.
• 7. Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G, Worel N, Lechner K, Greinix HT. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol. 1999;78(4):189-91.
• 6. Reiter, E., Greinix, H.T., Mitterbauer, G., Fischer, G., Keil, F., Mannhalter, C., Rabitsch, W., Schwarzinger, I., Worel, N., Lechner, K., Kalhs, P. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. Annals of Hematology. 1998;Volume 77, Issue 6, Pages 283-286.
• 5. Dettke M, Hlousek M, Kurz M, Leitner G, Rosskopf K, Stiegler G, Stohlawetz P, Worel N, Höcker P, Panzer S. Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion. 1998 May;38(5):449-53.
• 4. Höcker P, Kührer I, Worel N, Leitner G, Kalhs P, Greinix H, Gerhartl K. Positive selection of CD34+ cells by immune affinity. Beitr Infusionsther Transfusionsmed. 1997;34:166-70.
• 3. Worel, N., Greinix, H., Kalhs, P., Kührer, I., Zelenka, P., Schmidt, H., Höcker, P. Collection of peripheral blood stem cells (PBSC) from patients with multiple myeloma (MM) and autologous transplantation. Infusionstherapie und Transfusionsmedizin (from 1992 to 2002, continued as Transfusion Medicine and Hemotherapy) Volume 24, Issue 4, 1997, Page 238.
• 2. Worel N, Peters C, Gerhartl K, Wagner A, Jurko S, Höcker P. Collection of peripheral blood stem cells (PBSC) after chemotherapy and administration of rhGM-CSF in children weighing less than 17 kg. Transfus Sci. 1996;17(4):601-6.
• 1. Heinz, R., Fortelny, A., Schneider, B., Hopfinger, G., Worel, N., Möstl, M., Waldner, R., Tüchler, H., Pittermann, E., Hanak, H. Long-term follow-up of 1,654 consecutive non-hodgkin lymphoma patients-data from a single institution. Oncology Research and Treatment. 1995;18(3), pp. 231-239.

Reviews/Editorial/Commentaries

• 18. Nina Worel, Mahmoud Aljurf, Chloe Anthias, Andreas S Buser, Meghann Cody, Mirjam Fechter, Sebastian Galeano, Hildegard T Greinix, Annika M Kisch, Mickey B C Koh, Thilo Mengling, Grazia Nicoloso, Dietger Niederwieser, Michael A Pulsipher, Adriana Seber, Bronwen E Shaw, Heather E Stefanski, Galen E Switzer, Jeff Szer, Suzanna M van Walraven, Hung Yang, Jörg P Halter. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. The lancet haematology in press.
• 17. Buser A, Worel N. Extracorporeal Phototherapy. Transfus Med Hemother. 2020 Jun;47(3):197
• 16. Hopfinger G, Worel N. CAR T-cell therapy in diffuse large B-cell lymphoma. Memo - Magazine of European Medical Oncology. 2020;13(1), pp. 32-35.
• 15. Humpe, A., Körper, S., Schäfer, R., Klump, H., Worel, N. The Role of Transfusion Medicine Departments in the Process of Implementing Approved CAR-T Cell Therapies. Tumor Diagnostik und Therapie. 2019, 40(10), pp. 672-676.
• 14. Worel N, Mansouri Taleghani B, Strasser E. Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology. Transfus Med Hemother. 2019 Dec;46(6):394-406. doi: 10.1159/0
• 13. Hopfinger G, Jäger U, Worel N. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. Hemasphere. 2019 Mar 8;3(2):e185. doi: 10.1097/HS9.0000000000000185.
• 12. Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor T‑cell therapy—a hematological success story. Memo - Magazine of European Medical Oncology. 2018;11(2), 116-121
• 11. Worel N. Practical implementation - Essential elements resource tool. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):198-202.
• 10. Worel N. ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Transfus Med Hemother. 2016 Jan;43(1):3-12.
• 9. Greinix HT, Worel N, Just U, Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci. 2014 Jun;50(3):349-57.
• 8. Greinix, HT, Mitterbauer M, Rabitsch W, Worel N, Just U, Knobler R, Kalhs P. New developments in acute graft-versus-host disease. Memo - Magazine of European Medical Oncology. 2013, 6(2), pp. 98-101.
• 7. Auer-Hackenberg, L., Winkler, S., Graninger, W., Worel, N., Ramharter, M. Current evidence and future of automated erythrocyte exchange in the treatment of severe malaria. Wiener Klinische Wochenschrift. 2012,124(3 SUPPL.), 23-26
• 6. Worel N, Leitner GC. Clinical results of extracorporeal photopheresis. Transfusion Medicine and Hemotherapy. 2012,39(4),254-262
• 5. Worel N. Plerixafor – the magic bullet in stem cell mobilization failure? Editorial. Leuk Res. 2011 Feb 2.
• 4. Leitner GC, Worel N, Vogelsang H. Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease. Transfusion Medicine and Hemotherapy. 2010, 39(4),246-252
• 3. Greinix HT, Worel N. New agents for mobilizing peripheral blood stem cells. Transfus Apher Sci. 2009;41(1):67-71.
• 2. Worel N, Mayr W. Stem cell harvesting and transplantation. ISBT Science Series 2009;4:193-99.
• 1. Worel N, Kalhs P. AB0-incompatible allogeneic hematopoietic stem cell transplantation. Haematologica. 2008;93(11):1605-7.

Buch/Buchkapitel

• Editor von Best Practices of Apheresis in hematopoietic Cell Transplantation aus der Serie “Advances and Controversies in Hematopoietic Transplantation and Cell Therapy”
• Chapter 5: Mobilization Strategies: HPC(A) Collections for Autologous Hematopoietic Cell Transplants (Seite 51 bis 63), 2020, ISBN 978-3-319-55130-2
• Establishing a Hematopoietic Stem Cell Transplantation Unit
• Chapter 10: Donor/Recipient Selection, Work Up and Safety, 2018, ISBN 978-3-319-59356-2
• Extracorporeal Photopheresis Cellular Photoimmunotherapy
• Chapter 2: ECP in Patients with Bleeding Risks (Seite 22 bis 28), 2012, ISBN 978-3-11-027594-0

Positionen und Funktionen

• Seit 04/1994 Medizinische Universität Wien und Universitätsklinikum AKH Wien/Universitätsklinik für Transfusionsmedizin und Zelltherapie
• Seit 2019 Herstellungsleitung ATMPs
• Seit 2015 Etablierung des CAR-T Zellprogramms an der Universitätsklinik für Transfusionsmedizin und Zelltherapie in Zusammenarbeit mit der Klin. Abteilung für Hämatologie und Knochenmarktransplantation der Univ. Klinik für Innere Medizin I
• Seit 2005 Medizinische Leitung der Zell- & Gewebeentnahmeeinrichtung und Gewebebank
• Seit 2005 Bereichsleitung therapeutische Apheresen

Ausbildung

• 12/2002 Fachärztin für Allgemeinmedizin
• 03/1999 Notärzt:innendiplom
• 04/1994–04/1998 Fachärzt:innenausbildung Blutgruppenserologie und Transfusionsmedizin, Medizinische Universität Wien
• 10/1983–10/1989 Studium der Humanmedizin, Medizinische Universität Wien

Experimentelle und klinische Forschung

• 2016–2022 Klinische Studienaktivitäten als Principal Investigator und Subinvestigator im Bereich Zelltherapie
• 09/2018–11/2018 Fellowship an der Medizinischen Hochschule Hannover und Fraunhofer Institut für Zelltherapie und Immunologie Leipzig
• 10/2003 Habilitation und Lehrbefugnis für das Fach Blutgruppenserologie und Transfusionsmedizin an der Medizinischen Universität Wien: „Immunhämatologische Probleme nach allogener Knochenmarktransplantation“

Ehrungen, Auszeichnungen, Förderung

• 2019 Erwin Domanig Award of the Austrian Society for Blood Group Serology and Transfusion Medicine
• 2013 Best Oral Abstract Award of the German Society for Transfusion Medicine and Immunehematology
• 2011 Erwin Domanig Award of the Austrian Society for Blood Group Serology and Transfusion Medicine
• 2003 Award of the Austrian Society for Transplantation, Transfusion and Genetic, Austrotransplant

Peer-Review-Förderungen (§ 26)

1. Principal Investigator

• 2021 Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung
• 2010 Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien (BGM)

2. Subinvestigator

• 2010 EU Projekt: FP7-HEALTH-2010-single-stage “academic GMP”
• 2018 Trex A prospective controlled trial of in vitro expanded recipient regulatory T cell therapy and tocilizumab together with donor bone marrow infusion in HLA-mismatched living donor kidney transplant recipients (WWTF)

Industrie-Förderungen (§ 27)

1. Principal Investigator

• APN401-103 Phase 1b Open-Label, Multi-Center, Dose Escalation and Expansion Study of APN401 in Patients with Advanced Solid Tumors
• ATA129-EBV-205 An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
• ATA129-EBV-302 Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
• CCTL019B2206 A multicentre study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
• OPTIMIZE Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results

2. Subinvestigator

• M-2020-371 - Daly 2 A pivotal Phase II randomised, multicentre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with R-R DLBCL, who are not eligible for HD-CHT and Autologous Stem Cell Transplantation (“Clinical Study”)
• JCAR017-FOL-001 A phase 2, Open Label, Single-Arm, multicohort, Multi-Center Trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)
• CYTB323A12101 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL and DLBCL
• CTL19 H2301 Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
• CTL019J2101 Phase Ib study of tisagenlecleucel in combination with pembrolizumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients (PORTIA)
• JCAR017-BCM-001 A Phase 2, Single-Arm, Multi-Cohort, Multi-Center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma
• CCTL019A2205B Long Term Follow-Up of patients exposed to Lentiviral-based CD19 directed CART cell therapy
• CCTL019C2201 A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Medizinischer Werdegang

• Seit 06/2020 Assistenzärztin an der Universitätsklinik für Transfusionsmedizin und Zelltherapie, Medizinische Universität Wien
• 07/2021–09/2021 Medizinische Basisausbildung an der Univ. Klinik f. Hämatologie und Hämostaseologie, Medizinische Universität Wien
• 09/2019–02/2020 Medizinische Basisausbildung an der University Hospital Maribor, Slovenia
• 2013–2019 Studium der Humanmedizin an der Universität Maribor und der Medizinischen Universität Wien